

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/84234 A1**

(51) International Patent Classification<sup>7</sup>: G03C 5/00,  
C07H 19/00, 19/04

Gregory, M.; 640 Gooseberry Drive #903, Longmont, CO  
80503 (US).

(21) International Application Number: PCT/US01/13956

(74) Agents: SWANSON, Barry, J. et al.; Swanson &  
Bratschun, L.L.C., Suite 330, 1745 Shea Center Drive,  
Highlands Ranch, CO 80129 (US).

(22) International Filing Date: 1 May 2001 (01.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/201,561 1 May 2000 (01.05.2000) US  
60/265,020 30 January 2001 (30.01.2001) US

(71) Applicant: PROLIGO LLC [US/US]; Suite 207, 2995  
Wilderness Place, Boulder, CO 80301 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(72) Inventors: PIEKEN, Wolfgang; 4190 S. Hampton  
Circle, Boulder, CO 80301 (US). WOLTER, Andreas;  
Esmarchstrasse 125, 22767 Hamburg (DE). SEBESTA,  
David, P.; 1056 Katy Lane, Longmont, CO 80501 (US).  
LEUCK, Michael; 1235 Berea Drive, Boulder, CO 80305  
(US). LATHAM-TIMMONS, Hallie, A.; 4375 Whitney  
Place, Boulder, CO 80305 (US). PILON, John; 1160  
Princeton Drive, Longmont, CO 80503 (US). HUSAR,

(54) Title: METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGA-  
TION METHOD

(57) Abstract: This invention discloses a novel method for immobilizing molecules to a support. Specifically, this invention dis-  
closes a method of immobilizing derivatized biomolecules, such as oligonucleotides, using cycloaddition reactions, such as the  
Diels-Alder reaction. Included in this invention are the novel immobilized biomolecules that can be prepared according to the  
method of this invention.

WO 01/84234 A1

## METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD

### 5 FIELD OF THE INVENTION

This invention describes a novel method for immobilizing molecules on a support. Particularly, this invention describes a method for immobilizing biomolecules on a support using cycloaddition reactions, such as the Diels-Alder reaction.

### 10 BACKGROUND OF THE INVENTION

Applications for surface immobilized biomolecules are widespread and include nucleic acid sequencing, gene expression profiling, analysis for single nucleotide polymorphisms (SNPs) and evaluation of hapten-antibody or ligand-target interactions. An important subset of these techniques involves immobilization of oligonucleotide probes that employ Watson-Crick hybridization in the interaction with target nucleic acids such as genomic DNA, RNA or cDNA prepared via Polymerase Chain Reaction (PCR) amplification of sample DNA. Current technologies often involve formatting oligonucleotide probes for such analyses into microarrays on glass slides, silicon chips or wafers, micro titer plates or other supports including polyacrylamide gel matrices.

20 A variety of methods exist for immobilizing biomolecules, including non-covalent (hydrophobic or ionic interactions) as well as covalent methods. A number of these methods are summarized in Table 1. Methods involving covalent attachment are generally considered preferable, as more stringent conditions may be applied to the immobilized system for the reduction of non-specific ionic or hydrophobic associations (which raise background signal) without concern for the loss of the probe from the surface. Commonly employed covalent methods include condensation of amines with activated carbonyl groups on the surface, such as activated carboxylic acid esters, carbonates or isocyanates or isothiocyanates. Additionally, amine groups can be condensed with aldehydes under reductive amination conditions to afford secondary amine linkages between the surface and the biomolecule. Furthermore, amines can be condensed with electron deficient heterocycles via nucleophilic aromatic substitution as well as epoxide opening.

30 Cycloaddition reactions can be defined as any reaction between two (or more) moieties (either intra or intermolecular) where the orbitals of the reacting atoms form a cyclic array as the reaction progresses (typically in a concerted fashion although intermediates may be involved) along the reaction coordinate leading to a product. The

5 orbitals involved in this class of reactions are typically  $\pi$  systems although certain  $\sigma$  orbitals can also be involved. The number of electrons associated with this type of reaction are of two types:  $4n+2$  and  $4n$ , where  $n = 0, 1, 2, 3, 4$ , etc. Typical examples of cycloaddition reactions include Diels-Alder cycloaddition reactions, 1,3-dipolar cycloadditions and [2+2] cycloadditions.

10 The Diels-Alder reaction, by far the most studied cycloaddition, is the cycloaddition reaction between a conjugated diene and an unsaturated molecule to form a cyclic compound with the  $\pi$ -electrons being used to form the new  $\sigma$ -bonds. The Diels-Alder reaction is an example of [4+2] cycloaddition reaction, as it involves a system of  $4\pi$ -electrons (the diene) and a system of  $2\pi$ - (the dienophile). The reaction can be made to  
15 occur very rapidly, under mild conditions, and for a wide variety of reactants. The Diels-Alder reaction is broad in scope and is well known to those knowledgeable in the art. A review of the Diels-Alder reaction can be found in "Advanced Organic Chemistry" (March, J., ed.) 839-852 (1992) John Wiley & Sons, NY, which is incorporated herein by reference.

20 It has been discovered that the rate of Diels-Alder cycloaddition reactions is enhanced in aqueous solvents. (Rideout and Breslow (1980) J. Am. Chem. Soc. 102:7816). (A similar effect is also seen with 1,3-dipolar cycloaddition reactions (Engberts (1995) Tetrahedron Lett. 36:5389). This enhancement is presumably due to the hydrophobicity of the diene and dienophile reactants. (Breslow (1991) Acc. Chem. Res.  
25 24:159). This effect extends to intramolecular Diels-Alder reactions. (Blokzijl *et al.* (1991) J. Am. Chem. Soc. 113:4241). Not only is the reaction rate accelerated in water, but several examples of an increased endo/exo product ratio are also reported. (Breslow and Maitra (1984) Tetrahedron Lett. 25:1239; Lubineau *et al.* (1990) J. Chem. Soc. Perkin Trans. I, 3011; Grieco *et al.* (1983) Tetrahedron Lett. 24:1897). Salts which increase the  
30 hydrophobic effect in water, such as lithium chloride (Breslow *et al.* (1983) Tetrahedron Lett. 24:1901) and also monovalent phosphates (Pai and Smith (1995) J. Org. Chem. 60:3731) have been observed to further accelerate the rate of [4+2] cycloadditions.

In U.S. Application Serial Nos. 09/051,449, filed April 6, 1998; 08/843,820, filed April 21, 1997 and 09/402,430, filed October 7, 1999; each entitled "Method for Solution  
35 Phase Synthesis of Oligonucleotides," the Diels-Alder cycloaddition reaction is shown to be an ideal method for anchoring oligonucleotides onto resins. Resins derivatized with a

5 diene or dienophile are reacted with an oligonucleotide derivatized with a dienophile or diene, respectively, to yield the Diels-Alder cycloaddition product. In particular, Diels-Alder reactions between oligonucleotides derivatized with a diene and polymeric resins derivatized with maleimide groups and with phenyl-triazoline-diones (PTAD) are described. The resulting resins can be used as affinity chromatography resins.

10 U.S. Application Serial No. 09/341,337, filed July 7, 1999, entitled "Bioconjugation of Macromolecules," illustrates that cycloaddition reactions in general, such as the Diels-Alder reaction and 1,3-dipolar cycloaddition reactions, are an ideal replacement for current methods of conjugating macromolecules with other molecular moieties. The Diels-Alder reaction, in particular, is an ideal method for covalently linking  
15 large water soluble macromolecules with other compounds as the reaction rate is accelerated in water and can be run at neutral pH. (Rideout and Breslow (1980) J. Am. Chem. Soc. 102:7816). Additionally, the nature of the reaction allows post-synthetic modification of the hydrophilic macromolecule without excess reagent or hydrolysis of the reagent. With respect to conjugation to oligonucleotides, this technology has been aided  
20 by the ability to efficiently synthesize 2'-O-diene-nucleosides, which allows the conjugation site to be varied throughout the oligonucleotide or the option of having multiple conjugation sites.

The present invention describes a method for immobilizing molecules, particularly biomolecules, to a support using the cycloaddition bioconjugation method.

25 Immobilization of biomolecules via cycloaddition, particularly Diels-Alder reactions, offers the following major advantages over conventional methods (cf. Table 1): cycloaddition reactions establish a covalent and stable linkage between the linked compounds; the reaction proceeds with high chemoselectivity; functional groups of biomolecules do not interfere with the cycloaddition reaction; the cycloaddition reaction is  
30 orthogonal to other immobilization/labeling protocols, thus two-fold reactions are possible in one reaction mixture; in contrast to general techniques in organic synthesis, as discussed above, Diels-Alder reactions, can be carried out in aqueous phase, the Diels-Alder reaction is tremendously accelerated in water and is very fast at room temperature or slightly below; the cycloaddition reaction proceeds under neutral conditions in a one-step  
35 procedure; no by-products are formed during the reaction; no activators or additives are necessary to run the reaction and the moieties involved in the reaction (dienes and

5 dienophiles) are stable under various reaction conditions employed for conjugation or immobilization of biomolecules

Note, that throughout this application various citations are provided. Each citation is specifically incorporated herein by reference in its entirety.

## 10 SUMMARY OF THE INVENTION

The present invention describes a novel, chemoselective and highly efficient method for immobilizing molecules using cycloaddition reactions. The method of the invention offers advantages over existing immobilization methods that can suffer from cross-reactivity, low selectivity, mechanistic ambiguity and competitive hydrolysis of  
15 reactive groups.

In summary, the method of the instant invention comprises the step of reacting a derivatized molecule with a derivatized support capable of reacting with said derivatized molecule via a cycloaddition reaction. In a preferred embodiment, the derivatized molecule is a biomolecule, preferably an oligonucleotide, but could also be a hapten,  
20 carbohydrate, oligosaccharide, peptide and protein (including an antibody). The support is preferably glass or controlled pore glass (CPG), but could also be polypropylene, polystyrene, polyacrylamide or silicon. In a preferred embodiment, the cycloaddition reaction is a Diels-Alder cycloaddition reaction between the support and the biomolecule. Therefore, the biomolecule is preferably derivatized with one component of a Diels-Alder  
25 reaction, i.e., a diene or a dienophile, and the support is derivatized with the appropriate counterpart reactant, i.e., a dienophile or a diene, respectively.

This invention includes a reaction scheme for producing a wide variety of immobilized biomolecules using cycloaddition reactions as typified by the Diels-Alder cycloaddition reaction. The method of this invention can be extended to the  
30 immobilization of any molecule, particularly biomolecules on any support that can be appropriately derivatized.

The method of this invention can be extended to all  $4n$  and  $4n+2$  cycloadditions (where  $n = 0, 1, 2, 3, 4$ , etc.). This includes, but is not limited to Diels-Alder cycloadditions, 1,3-dipolar cycloadditions, ene cycloaddition reactions and  $[2+2]$  (a  $4n$   
35 type) cycloadditions, such as ketene additions and photochemical  $[2+2]$  additions.

Also described herein is a method by which surfaces, preferably glass microscope slides or CPG, may be converted into reactive elements for the cycloaddition immobilization method of the invention by deposition of silane monolayers appropriately functionalized with reaction components for cycloaddition reactions.

Also included in this invention are any novel immobilized and derivatized molecules and derivatized supports produced by the method of the invention.

The method of the invention is applicable to the fields of biomolecule array fabrication for research, development and clinical diagnostic applications relating to nucleic acid sequencing, gene expression profiling, analysis of single nucleotide polymorphisms (SNPs) and evaluation of hapten-antibody or ligand-target interactions.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a fluorescence scan of polyacrylamide gel loaded with 1, 2 and 3  $\mu$ L of fluorescein labeled compound (26), the synthesis of which is described in Example 6.

Figure 2 is a fluorescence scan of a glass slide showing maleimide functionalization on the lower half of the slide, that was treated with maleimide-silane (19), followed by reaction with a thiol containing-fluorescein reagent (SAMSA-reagent), as described in Example 7.

Figure 3 is a fluorescence scan of maleimide derivatized CPG. In Figure 3A native CPG was first treated with maleimide silane (19), followed by staining with SAMSA-reagent. In Figure 3B native CPG was treated with SAMSA-fluorescein to serve as a control.

Figure 4 is a fluorescence scan of a glass slide showing diene functionalization on the lower half of the slide that was treated with diene-silane reagent (20), followed by reaction of the diene functionalized slide with fluorescein-5-maleimide, as described in Example 8.

Figure 5 is a fluorescence scan of diene functionalized CPG. In Figure 5A CPG was treated with diene-silane (20), followed by staining with fluorescein-5-maleimide. In Figure 5B native CPG was treated with fluorescein-5-maleimide to serve as a control.

Figure 6 shows a diagram of a slide showing placement of septa and contents of septa for demonstration of Diels-Alder surface immobilization of an oligonucleotide on maleimide functionalized glass micro slides as described in Example 9.

5           Figure 7 illustrates fluorescence scans of glass slides showing successful Diels-Alder surface immobilization of 5'-diene-oligonucleotide (23) on maleimide-functionalized glass micro slides. Slide "1" was pre-treated with 2N NaOH then hot 2N HCl prior to maleimide-functionalization. Slide "2" was pre-treated only with 2N HCl. Spots visible on each slide are where compound (23) came into contact with the  
10 maleimide-functionalized portion of the slide prior to hybridization with complementary 5'-fluorescein-oligonucleotide (27); areas of the slides that came into contact with controls showed no response.

          Figure 8 illustrates the conjugation of diene-oligonucleotide (23) to maleimide-coated micro titer plates after hybridization with complementary fluorescein labeled  
15 sequence 5'-fluorescein-(CA)<sub>10</sub> (27) (SEQ ID NO:2). Wells 1-3 were treated with diene-oligonucleotide (23), pure, and wells 4-6 were treated with diene-oligonucleotide (23), crude. Wells 1A-6A are the corresponding oligonucleotide (22) controls. Wells 7 and 7A are the buffer controls. Wells 1, 1A, 4, 4A were incubated at pH = 5.5, wells 2, 2A, 5, 5A at pH = 6.5 and wells 3, 3A, 6A at pH = 7.7.

20           Figure 9 illustrates graphically the relation between the loading of CPG (10 mg) with oligonucleotide (24) and the concentration of oligonucleotide (24) in solution.

          Figure 10 illustrates graphically the relation between the loading of CPG (10 mg) with oligonucleotide and the incubation time with oligonucleotide (24).

          Figure 11 illustrates fluorescence scans of glass slides showing successful Diels-Alder surface immobilization of maleimide-oligonucleotide (26) on diene functionalized  
25 glass micro slides. Slide "1" is prior to the wash with phosphate buffered saline (PBS) illustrating the necessity of the wash to remove non-covalently bound oligonucleotide from the glass surface. Slide "2" is after the PBS wash. The single fluorescent response visible on the slide is where compound (26) came into contact with the diene-  
30 functionalized portion of slide prior to hybridization with complementary-5'-fluorescein-oligonucleotide (27). After the PBS wash, areas of the slide that came into contact with controls showed no response.

          Figure 12 illustrates fluorescence scans of CPG samples showing Diels-Alder surface immobilization of an oligonucleotide (maleimide-oligonucleotide (26)) on diene-  
35 functionalized CPG. Figure 12A is prior to the wash with a mixture of 5x0.3 M sodium citrate and 3 M sodium chloride (SSC) and Figure 12B is after the SSC wash. The

5 fluorescent response visible on the sample labeled "2A" is where compound (26) came into contact with diene-functionalized CPG prior to hybridization with complementary 5'-fluorescein-oligonucleotide (27). After the SSC wash, the control samples labeled "2B" and "2C" showed relatively little response.

Figure 13 is an overlaid Biacore sensorgram illustrating the reproducibility of the formation of the maleimide-coated BIAcore flow cell surface (37) described in Example 15.

Figure 14 is a Biacore sensorgram of the product of the Michael-addition between maleimide-coated BIAcore flow cell surface (37) and MeO-PEG-SH, which is described in Example 16.

15 Figure 15 is a Biacore sensorgram of the product of the Diels-Alder reaction between maleimide-coated BIAcore flow cell surface (37) and PEG-diene substrate (34), described in Example 16.

Figure 16 is a Biacore sensorgram of the product of the Diels-Alder reaction between maleimide-coated BIAcore flow cell surface (37) and PEG-anthracene substrate (36), described in Example 17.

Figure 17 is a Biacore sensorgram of the product of the Diels-Alder reaction between maleimide-coated BIAcore flow cell surface (37) and cyclohexadiene modified oligonucleotide (29), described in Example 18.

Figure 18 is a Biacore sensorgram of the product of the Diels-Alder reaction between maleimide-coated BIAcore flow cell surface (37) and cyclohexadiene modified oligonucleotide (29), upon hybridization of the immobilized sequence with its complementary oligonucleotide sequence.

Figure 19 illustrates the functionalization of glass microscope slides with anthracene-silane reagent (42).

30

## DETAILED DESCRIPTION OF THE INVENTION

The present invention includes a method for immobilizing molecules on a support. Specifically, the present invention describes the use of cycloaddition reactions, in particular the Diels-Alder cycloaddition reaction for the chemoselective immobilization of molecules on a support.

35



5           The method of the instant invention comprises the step of reacting a derivatized molecule with a derivatized support capable of reacting with said derivatized molecule via a cycloaddition reaction. In a preferred embodiment, the derivatized molecule is a biomolecule, most preferably an oligonucleotide and the support is preferably glass or controlled pore glass (CPG). In a preferred embodiment, the cycloaddition reaction is a  
10   Diels-Alder cycloaddition reaction. Therefore, the biomolecule is derivatized with one component of a Diels-Alder reaction, i.e., a diene or a dienophile, and the support is derivatized with the appropriate counterpart reactant, i.e., a dienophile or a diene, respectively.

          This invention includes a reaction scheme for producing a wide variety of  
15   immobilized biomolecules using cycloaddition reactions as typified by the Diels-Alder cycloaddition reaction. The method of this invention can be used to immobilize any molecule, particularly biomolecules, on any support that can be appropriately derivatized.

          Certain terms used to describe the invention are described herein as follows:

          "Oligonucleotide" refers to a polynucleotide formed from a plurality of linked  
20   nucleotide units. The nucleotide units each include a nucleoside unit linked together via a phosphate linking group. The term oligonucleotide also refers to a plurality of nucleotides that are linked together via linkages other than phosphate linkages such as phosphorothioate linkages. The oligonucleotide may be naturally occurring or non-naturally occurring. In a preferred embodiment the oligonucleotides of this invention have  
25   between 1-1,000 nucleotides.


          For the purposes of this invention "nucleobase" will have the following definition. A nucleobase is a purine or a pyrimidine base. Nucleobase includes all purines and pyrimidines currently known to those skilled in the art or any chemical modifications thereof. The purines are attached to the ribose ring through the nitrogen in the 9 position  
30   of the purine ring and the pyrimidines are attached to the ribose ring through the nitrogen in the 1 position of the pyrimidine ring. The pyrimidine can be modified at the 5- or 6- position of the pyrimidine ring and the purine can be modified at positions 2-, 6- or 8- of the purine ring. Certain modifications are described in U.S. Patent Applications Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and  
35   Novel 2' Modified Pyrimidines Intramolecular Nucleophilic Displacement" and U.S. Patent No. 5,428,149, entitled "Method for Palladium Catalyzed Carbon-Carbon Coupling

5 and Products" which are herein incorporated by reference. More specifically a nucleobase includes, but is not limited to, uracil, cytosine, N4-protected cytosine, 4-thiouracil, isocytosine, 5-methyluracil (thymine), 5-substituted uracils, adenine, N6-protected adenine, guanine, N2-protected guanine, 2,6-diaminopurine, halogenated purines as well as heterocycles meant to mimic the purine or pyrimidine ring, such as imidazole.

10 A "diene" is defined as a molecule bearing two conjugated double bonds. The diene may even be non-conjugated, if the geometry of the molecule is constrained so as to facilitate a cycloaddition reaction (Cookson (1964) J. Chem. Soc. 5416). The atoms forming these double bonds can be carbon or a heteroatom or any combination thereof.


A "dienophile" is defined as a molecule bearing an alkene group, or a double bond  
15 between a carbon and a heteroatom, or a double bond between two heteroatoms.

The dienophile can be any group, including but not limited to, a substituted or unsubstituted alkene, or a substituted or unsubstituted alkyne. Typically, the dienophile is a substituted alkene of the formula  $C=C-Z$  or  $Z'-C=C-Z$ , wherein Z and Z' are electron withdrawing groups independently selected from the group consisting of CHO, COR, COOH, COCl, COaryl, CN, NO<sub>2</sub>, aryl, CH<sub>2</sub>OH, CH<sub>2</sub>Cl, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CN, CH<sub>2</sub>COOH, halogen, or C=C. In certain cases the groups attached to the alkene unit can be electron donating groups, including but not limited to phenyl rings, conjugated double bonds, alkyl groups, OMe groups or other X-alkyl moieties wherein X is an electron donating group (these type of dienophiles undergo cycloadditions that are known generally as reverse  
20 electron demand cycloadditions). Other examples of dienophiles include compounds having the formula,  $R_2C=X$ , wherein X is a heteroatom, selected from the group consisting of oxygen, nitrogen, phosphorus and sulfur. For example, molecules bearing a primary amino group, such as amino acids or a lysine containing peptide, can be converted to efficient dienophiles by reaction with formaldehyde to yield their corresponding iminium salts as illustrated below. The latter undergo Diels-Alder cycloaddition with  
25 macromolecules bearing a diene group under mild conditions in aqueous solvents.




5 A "1,3-dipole" is defined as a compound that contains a consecutive series of three atoms, a-b-c, where atom a contains a sextet of electrons in its outer shell and atom c contains an octet with at least one unshared pair of electrons in its outer shell. Because molecules that have six electrons in the outer shell of an atom are typically unstable, the a-b-c atom example is actually one canonical structure of a resonance hybrid, where at least  
 10 one structure can be drawn. 1,3-dipoles can be divided into two main groups:

1) Systems in which one of the canonical forms has a double bond on the sextet atom (atom a) and the other canonical form has a triple bond on that atom:




2) Systems where the dipolar canonical form has a single bond on the sextet atom (atom a) and the other canonical form has a double bond on that atom:



For a review of this reaction type see "Advanced Organic Chemistry" (March, J., ed.) 836-839 (1992) John Wiley & Sons, NY, and "Frontier Orbitals and Organic Chemical Reactions" (I. Fleming) 148-161 (1976) John Wiley & Sons, Ltd. Typical  
 20 examples of 1,3-dipoles include, but are not limited to nitrile ylids, nitrile imines, nitrile oxides, diazoalkanes, azides, azomethine ylids, azomethine imines, nitrones, carbonyl ylids, carbonyl imines and carbonyl oxides.

A "1,3-dipolarophile" is defined in the same manner as a "dienophile" or "diene" (as described above). The macromolecule can be attached to either (or both) the 1,3-  
 25 dipole or the 1,3-dipolarophile.

A "1,3-dipolar cycloaddition reaction" can be generally represented as follows:



An "Ene reaction" can be generally represented as follows:

11



5

The reaction partners in an Ene reaction are referred to as an "ene" and an "enophile." An "enophile" is defined in the same manner as a "dienophile" (see the above description for dienophile). An "ene" can be any unsaturated group, including but not limited to, a substituted or unsubstituted alkene, or a substituted or unsubstituted alkyne. Typically, the "ene" is a substituted alkene of the formula  $X-C=CH-CH_2-$  or  $X'-C=C-X-CXH-$ , wherein X and X' are electron donating groups. The macromolecule can be attached to either (or both) the ene component or the enophile component.

10

"Bioconjugate" as defined herein refers to any macromolecule which has been derivatized with another molecular entity. "Bioconjugation" or "Conjugation" refers to the derivatization of a macromolecule with another molecular entity.

15

As used herein a "support" refers to glass, including but not limited to controlled pore glass (CPG), glass slides, glass fibers, glass disks, materials coated with glass, silicon chips and wafers including, but not limited to metals and composites containing glass; polymers/resins, including but not limited to polystyrene (PS), polyethylene glycol (PEG), copolymers of PS and PEG, copolymers of polyacrylamide and PEG, copolymers containing maleimide or maleic anhydride, polyvinyl alcohol and non-immunogenic high molecular weight compounds; and large biomolecules, including but not limited to polysaccharides, such as cellulose, proteins and nucleic acids. The support can be, but is not necessarily, a solid support.

20

As used herein "immobilization" refers to the attachment, via covalent bond, to a support. Immobilization includes a functionality on the support or a derivatized support.

25

The term "functionality" as used herein refers to functional groups, including but not limited to alcohols, carboxylates, amines, sulfonic acids and halides, that allow the attachment of one component of the cycloaddition system (e.g. a diene or a dienophile).

30

As used herein "derivatized" refers to molecules and/or supports that have been functionalized with a moiety capable of undergoing a cycloaddition reaction. A molecule or support that bears a moiety capable of undergoing a cycloaddition reaction without functionalization also falls within this definition. Examples of moieties capable of undergoing a cycloaddition reaction, include but are not limited to a diene, dienophile, 1,3-

5 dipole, 1,3-dipolarophile, ene, enophile or other moiety capable of undergoing a cycloaddition reaction.

The term "molecule" includes, but is not limited to biomolecules, macromolecules, diagnostic detector molecules (DDM's) and other small molecules, particularly small molecules for use in combinatorial chemistry.

10 As used herein a "biomolecules" include, but are not limited to nucleic acids, oligonucleotides, proteins, peptides and amino acids, polysaccharides and saccharides, glycoproteins and glycopeptides (in general, glycoconjugates) alkaloids, lipids, hormones, drugs, prodrugs, antibodies and metabolites.


The term "macromolecules" as used herein refers to the product of the coupling of  
15 two macromolecules via cycloaddition.

"Diagnostic detector molecules" ("DDM's") include, but are not limited to fluorescent, chemiluminescent, radioisotope and bioluminescent marker compounds; antibodies, biotin and metal chelates.

As used herein "cycloaddition reaction" refers to any reaction that occurs between  
20 two reactants by a reorganization of valence electrons through an activated complex, which is usually a cyclic transition state. The orbitals involved in this class of reactions are typically  $\pi$ -systems although certain  $\sigma$ -orbitals can also be involved. The number of electrons associated with this type of reaction are of two types;  $4n+2$  and  $4n$ , where  $n = 0, 1, 2, 3, 4$ , etc. Typical examples of cycloaddition reactions include, but are not limited to  
25 [1+2]-cycloaddition, such as reaction between carbenes and olefins, [2+2]-cycloaddition, such as reaction between olefins or reaction between ketenes and olefins, [3+2]-cycloaddition, such as 1,3-dipolar cycloaddition, [2+4]-cycloaddition, such as the Diels-Alder reaction and ene reaction, [4+6]-cycloaddition, and cheletropic reactions. Types of reactants involved in cycloaddition reactions include, but are not limited to, olefins,  
30 including but not limited to alkenes, dienes etc with or without heteroatoms, alkynes, with and without heteroatoms, aromatic compounds, such as anthracene, 1,3-dipoles, carbenes and carbene-precursors.

The "derivatized oligonucleotides" of this invention are generally represented by the following formulas:

13



5

wherein

B is a nucleobase;

A and A' are 2'-sugar substituents;

10 W is independently selected from the group consisting of an oligonucleotide having between 1-1000 nucleobases, X or H; and

X is a diene, dienophile, 1,3-dipole, 1,3 dipolarophile, ene, enophile, alkene, alkyne or other moiety capable of undergoing a cycloaddition reaction, additionally when X is attached to nucleobase B it can be attached to a carbon atom, an exocyclic nitrogen or  
 15 an exocyclic oxygen.

In a preferred embodiment of the invention:

A and A' are independently selected from the group consisting of H,  $^2\text{H}$ ,  $^3\text{H}$ , Cl, F, OH,  $\text{NHOR}^1$ ,  $\text{NHOR}^3$ ,  $\text{NHNHR}^3$ ,  $\text{NHR}^3$ ,  $=\text{NH}$ ,  $\text{CHCN}$ ,  $\text{CHCl}_2$ , SH,  $\text{SR}_3$ ,  $\text{CFH}_2$ ,  $\text{CF}_2\text{H}$ ,  $\text{CR}_2^2\text{Br}$ ,  $-(\text{OCH}_2\text{CH}_2)_n\text{OCH}_3$ ,  $\text{OR}^4$  and imidazole (see United States Patent Application  
 20 Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of 2' Modified Pyrimidines Intramolecular Nucleophilic Displacement," which is incorporated herein by reference);

$\text{R}^1$  is selected from the group consisting of H and an alcohol protecting group;

5  $R^2$  is selected from the group consisting of =O, =S, H, OH,  $CCl_3$ ,  $CF_3$ , halide, optionally substituted  $C_1$ - $C_{20}$  alkyl (including cyclic, straight chain, and branched),  $C_2$ - $C_{20}$  alkenyl,  $C_6$ - $C_{20}$  aryl,  $C_1$ - $C_{20}$  acyl,  $C_1$ - $C_{20}$  benzoyl,  $OR_4$  and esters;

$R^3$  is selected from the group consisting of  $R^2$ ,  $R^4$ , CN,  $C(O)NH_2$ ,  $C(S)NH_2$ ,  $C(O)CF_3$ ,  $SO_2R^4$ , amino acid, peptide and mixtures thereof;


10  $R^4$  is selected from the group consisting of an optionally substituted hydrocarbon ( $C_1$ - $C_{20}$  alkyl,  $C_2$ - $C_{20}$  alkenyl,  $C_2$ - $C_{20}$  alkynyl), an optionally substituted heterocycle, t-butyltrimethylsilyl ether, triisopropylsilyl ether, nucleoside, carbohydrate, fluorescent label and phosphate;

Most preferably A is selected from the group consisting of H, OH,  $NH_2$ , Cl, F,  $NHOR^3$ ,  $OR^4$ ,  $OSiR^4_3$ . (See United States Patent Application Serial No. 08/264,029, filed 15 June 22, 1994, entitled "Novel Method of Preparation of 2' Modified Pyrimidines Intramolecular Nucleophilic Displacement," filed June 22, 1994); and

X includes, but is not limited to an alkyl or substituted alkyl group bearing a conjugated diene unit, an alkoxy or substituted alkoxy group bearing a conjugated diene 20 unit,  $CH_2CH_2CH=CHCH_2CH_2O$ , maleimide substituted alkoxy groups, dienophile substituted alkoxy groups, an alkylamino group or substituted alkylamino group bearing a conjugated diene unit, maleimide substituted alkylamino groups or substituted alkylamino groups, an alkylamino group or substituted alkylamino group bearing a dienophile moiety, a nitrile ylid, nitrile imine, nitrile oxide, diazoalkane, azide, azomethine ylid, azomethine 25 imine, nitron, carbonyl ylid, carbonyl imine and carbonyl oxide.

The alkyl groups on all the above listed moieties can have between 1-50 carbons, preferably 1-30 carbons.

As used herein a "linking molecule" is a molecular entity that connects two or more molecular entities through covalent interactions. More specifically a linking 30 molecule is a multifunctional molecule that can be used to derivatize a molecule or support with a diene, dienophile or other moiety capable of undergoing a cycloaddition reaction. The linking molecules of this invention are generally represented by the following formulas:




35 wherein

X is as defined above;

5 n is an integer from 1-20; and

L is a linker which includes, but is not limited to, compounds of the following general formula:



wherein

10 m, n, o is equal to 0, 1, 2 and

Y is selected from NH, O, NH(CO)O, NH(CS)O, NH(CO)NH, NH(CO), S-S-S-, Si(OR)<sub>3</sub> and SiR<sub>2</sub> wherein

R is selected from alkyl, aryl, substituted alkyl or substituted aryl, each having between 1-50 carbon atoms.

15 Other obvious substitutions for the substituents described above are also included within the scope of this invention, which is not limited to the specific, but rather the generalized formula of reaction.

Cycloaddition reactions, particularly Diels-Alder reactions, are uniquely suited as a general method for the immobilization of molecules, particularly biomolecules to a support. The cycloaddition of a diene and a dienophile is highly chemoselective and only a suitably electronically configured diene and dienophile pair will react. The reaction proceeds under mild conditions in a reasonable time-frame. Biomolecules such as nucleic

20



5 acids, oligonucleotides, proteins, peptides, carbohydrates, polysaccharides, glycoproteins, antibodies and lipids generally do not contain moieties that can undergo such a cycloaddition reaction. Thus, by specific introduction of a diene and dienophile reaction partner, biomolecule immobilization to a support becomes possible with unprecedented specificity.

10 The high selectivity of a diene or dienophile for reaction with the corresponding dienophile or diene, respectively, eliminates the need to protect functional groups during the synthesis of biomolecules, such as oligonucleotides or peptides. This is a tremendous practical advantage over other functional groups used for immobilization in biomolecular synthesis, in which the limited selectivity of the protection chemistry often determines the  
15 immobilization yields. Additionally, the diene and dienophiles are not susceptible to the side-reactions typically encountered in known immobilization methods. Because they do not undergo hydrolysis or solvolysis reactions, these reactions can be performed in aqueous media at near stoichiometric concentrations and thus conserve precious reagent. The lack of such side reactions allows immobilization of biomolecules in unprecedented  
20 yields and purities. The Diels-Alder cycloaddition reaction is accelerated by aqueous solvents and therefore, uniquely suited for the derivatization or immobilization of hydrophilic biomolecules. Finally, this method is typically much less pH sensitive than most known alternatives.

In one embodiment of the present invention the biomolecule is an oligonucleotide.  
25 The solvent of choice for the derivatization of oligonucleotides is water, due to the highly anionic nature of these molecules. Thus, an optimal reaction for the immobilization of such groups proceeds readily in water, and displays no side reactions with water, such as hydrolysis of any of the reactants. Based on these criteria for optimal and specific immobilization of oligonucleotides, this disclosure describes the use of Diels-Alder  
30 cycloadditions for the chemoselective and efficient immobilization oligonucleotides on a support. Thus, an oligonucleotide bearing either a diene modified nucleoside or non-nucleoside phosphate diester group, or a dienophile modified nucleoside or non-nucleoside phosphate diester group can be reacted with a support bearing either a dienophile or a diene moiety, respectively.

35 The diene or dienophile moiety can be incorporated into the oligonucleotide at any position in the chain, for instance, by introduction of a 5-(3,5-hexadiene)-2'-deoxyuridine

5 nucleoside (See U.S. Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2'-modified Nucleosides by Intramolecular Nucleophilic Displacement," which is incorporated herein by reference in its entirety). Alternatively, the diene or dienophile moiety can be introduced as a 2'-O-(3,5-hexadiene)-uridine nucleoside. A diene moiety can also be introduced to the  
10 oligonucleotide as a diene-bearing non-nucleoside phosphoramidite, such as 3,5-hexadiene-N,N-diisopropyl-2-cyanoethyl phosphoramidite. Reaction of the diene modified oligonucleotide, such as a 5'-terminal 3,5-hexadienephosphate oligonucleotide, with the dienophile modified support, such as maleimide derivatized glass, leads to efficient immobilization of the oligonucleotide.

15 The method of this invention can be extended to the immobilization of any molecule that can be derivatized with a diene, dienophile or other reactive group capable of undergoing a cycloaddition reaction without limitation. For example, the method can be extended to the immobilization of peptides and proteins with any support capable or being derivatized. A peptide or protein that contains an amino acid building block which  
20 has been derivatized with the diene or dienophile, such as O-3,5-hexadiene-tyrosine or serine, or N-maleimidolysine, can be immobilized on any support using the method described herein, without limitation. Natural molecules, such as proteins, can be derivatized with a diene or dienophile bearing a heterobifunctional crosslinking reagent, such as the NHS ester of 3-(4-maleimidophenyl)-propionic acid (Pierce), which allows  
25 subsequent conjugation to a support bearing a corresponding diene or dienophile group.

Polyethylene glycol is often conjugated to biomolecules to reduce their immunogenicity and to increase their residence time *in vitro*. The method of this invention allows immobilization of biomolecules, such as oligonucleotides or peptides, bearing a diene, dienophile or other reactive group capable of undergoing a cycloaddition  
30 reaction with another polymer or resin, such as polyethyleneglycol or polystyrene bearing one or several corresponding diene, dienophile or other groups capable of undergoing cycloaddition reactions.

Example 1 (Scheme 1) describes the synthesis of 5-hydroxymethylcyclohexa-1,3-diene (5).

35 Example 2 (Scheme 2) describes the preparation of NHS reagent (10) from cyclohexadiene alcohol (5).

5           Example 3 (Scheme 3) describes the synthesis of the diene amidite linker (16) from amino-linker (12). Amino-linker (12) was developed in mimesis of a nucleoside containing a primary (as 5'-OH) and a secondary hydroxyl group (as 3'-OH). This allows the conjugation of the linker on either the 3'- or 5'-end of any oligonucleotide. The attachment of various moieties to the oligonucleotide (e.g., dienes or dyes) is achieved via  
10 the linker's amino functionality. Therefore, compound (12) is recognized as a universal linker for conjugation of oligonucleotides.

          Example 4 (Scheme 4) describes the synthesis of maleimide-trialkoxysilane (19), which is used to functionalize glass surfaces.

          Example 5 describes the synthesis of diene-trialkoxysilane (20) for the  
15 functionalization of glass surfaces.

          Example 6 describes the synthesis of three 5' functionalized oligonucleotides, compounds (23), (24) and (26). Compounds (23) and (23) (Scheme 6) are functionalized at the 5' end with a diene by reaction with diene-linker amidite (16). Compound (26) (Scheme 7) is functionalized at the 5' end with a maleimide by reaction with  
20 maleimidopropionic acid N-hydroxysuccinimide ester (compound 18, Scheme 4).

          Examples 7 and 8 describe a method for the functionalization of two glass surfaces, specifically glass slides and CPG, with both a diene and a dienophile. Glass surfaces are derivatized with reactive moieties capable of undergoing cycloaddition reactions by deposition of silane monolayers appropriately functionalized for  
25 cycloaddition reaction. Specifically, Example 7 describes the functionalization of the two glass surfaces with maleimide dienophile (19) (Scheme 8). Example 7 also describes methods for the detection of the maleimide functionalized surfaces. The maleimide derivatized surfaces are detected by staining with a thiol-fluorescein reagent, which reacts with the maleimide via a Michael-addition as illustrated in Scheme 9. The presence of  
30 fluorescein bound to the surfaces is then detected with a Molecular Dynamics' Typhoon Fluorescence Scanner using a green laser to excite the surface-bound fluorescein followed by detection of emission using a 526 nm filter.

          Example 8 describes the functionalization of the two glass surfaces with diene (20) (Scheme 10). Example 8 also describes methods for the detection of the functionalized  
35 surfaces. The diene derivatized surfaces are detected by Diels-Alder reaction with a fluorescein maleimide as illustrated in Scheme 11.

5           Example 9 (Scheme 12) describes the Diels-Alder reaction between the 5' diene functionalized oligonucleotide (23) and maleimide functionalized glass slides and microtiter plates. This reaction demonstrates the Diels-Alder surface immobilization of an oligonucleotide (Scheme 12). Detection of the surface-bound oligonucleotide was achieved by its hybridization to a fluorescein-labeled complementary sequence (27) and  
10       detection of fluorescence. The results of this Example are set forth in Figure 8.

          Example 10 describes the Diels-Alder reaction between maleimide-CPG and diene derivatized oligonucleotide (24). In Example 9, the conjugation of the diene-oligonucleotide to the maleimide derivatized support was detected by the fluorescence of a labeled complementary sequence after hybridization. This method of detection, however,  
15       gives a qualitative result, but does not allow the quantitative determination of surface loading. In Example 10, a different detection method was selected for determination of immobilized oligonucleotide in order to obtain a quantitative determination of surface loading. For purposes of illustration, diene(DMT)-oligonucleotide (24) was used. After Diels-Alder reaction between diene (24) and maleimide, the surface bound amount of  
20       oligonucleotide (loading) is calculated after the cleavage of the DMT-group by photometric detection of the DMT-cation as illustrated in Scheme 12.

          Maleimide-derivatized CPG was incubated with increasing amounts of oligonucleotide (24) in order to demonstrate the relation between oligonucleotide immobilization (as CPG loading) and the amount of diene-oligonucleotide in solution.  
25       Using this method the typical range of oligonucleotide loading was calculated to be 0.8-1.7  $\mu\text{mol/g}$  (Table 2, Figure 9). The results obtained from this experiment also showed that not all maleimide-sites were reacted with diene-oligonucleotide and that the loading can be further increased by treatment with larger amounts of (24) by achieving an exponential dependence instead of a linear curve fit.

30       The kinetic relationship between loading and incubation time was also demonstrated. As expected an exponential curve was obtained, but the plateau of the curve was not reached in the time-frame applied for the experiment (Table 3, Figure 10). After approximately 100 minutes a saturation (by consumption of all oligonucleotide (24) in solution) was achieved. The most interesting result shows that even after an incubation  
35       time of 5 minutes, a loading of 0.4  $\mu\text{mol/g}$  was obtained. Compared with the data from the

5 first example, the concentration of 17 applied in this example is too low to saturate all of the maleimide sites of the CPG support.

Example 11 (Scheme 14) describes the conjugation of 5'-maleimide derivatized oligonucleotide (26) to diene coated glass surfaces. The demonstration of conjugation was achieved by hybridization with the labeled complementary sequence (27) and the detection  
10 of fluorescence as described above.

Example 12 (Scheme 15) describes the synthesis of diene modified oligonucleotide (29) from NHS reagent (10), the synthesis of which is described in Example 2.

Example 13 (Scheme 16) describes the HPLC monitoring of a Diels-Alder reaction employing a cyclohexadiene derivatized oligonucleotide. To confirm the Diels-Alder  
15 reactivity of diene conjugate (29), labeling with commercially available maleimide dienophiles (30) and (31) were carried out. The progress of the reaction was monitored by analytical anion exchange chromatography with samples taken every 5 minutes. Treatment of (29) with N-ethyl maleimide (30) resulted in complete conversion to adduct (32) within 5 minutes, while biotin maleimide 31 required 20 minutes.

20 Example 14 (Scheme 17) describes the synthesis of diene modified polyethylene glycol substrates (34). Example 14 (Scheme 18) also describes the synthesis of anthracene derivative (36).

Example 15 (Scheme 19) describes the preparation of a dienophile CM5 BIAcore flow cell surface.

25 Example 16 (Scheme 20) describes a comparison of surface derivatization via PEG-SH (Michael-addition) vs PEG-diene (Diels-Alder surface immobilization).

Example 17 (Scheme 21) describes the Diels-Alder reaction of dienophile derivatized CM5 BIAcore flow cell surface (37) with anthracene derivative (36) (preparation described in Example 14), using the method described in Example 16 to  
30 provide compound (38).

Example 18 (Scheme 22) describes the surface immobilization of the cyclohexadiene modified oligonucleotide (29) to the dienophile derivatized CM5 BIAcore flow cell surface (37), followed by hybridization with the complementary oligonucleotide sequence.

35 Example 19 (Scheme 23) describes the synthesis of anthracene-silane reagent (42).


5 Example 20 (Scheme 24) illustrates the functionalization of glass slides with anthracene-silane reagent (42).

The following examples are provided to explain and illustrate the present invention and are not to be taken as limiting of the invention.

## 10 EXAMPLES

### Example 1. Preparation of Cyclic Diene Alcohol (5)

Scheme 1 illustrates the preparation of cyclohexadiene (5). Briefly, the synthesis of diene-alcohol (5) was obtained from alcohol (1) in four steps by a scaleable and very convenient procedure as outlined in Scheme 1. This diene has been synthesized via a  
15 different route by Roth *et al.* ((1993) Chem. Ber. 126:2701-2715).



Synthesis of 4-(*tert*-butyldimethylsilyloxymethyl)-cyclohex-1-ene (2). To a stirred solution of 1,2,3,6-tetrahydrobenzylalcohol (1) (1.12 g, 10 mmol) and imidazole (1.36 g, 20 mmol) in DMF (10 mL) was added TBDMSCl (1.81 g, 12 mmol). After 20 hours, the mixture was treated with brine (100 mL) and the product was extracted with hexanes (3x80 mL). The combined organic layers were washed with brine (100 mL), dried over  $\text{MgSO}_4$  and evaporated *in vacuo* to give compound (2) (2.26 g, 100%) as colorless liquid.  $R_f$  0.29 (hexanes).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  5.65 - 5.64 (m, 2H), 3.48 (d,  $J = 2.3$  Hz, 1H), 3.45 (d,  $J = 2.3$  Hz, 1H), 2.08 - 2.00 (m, 3H), 1.82 - 1.66 (m, 3H), 1.32 - 1.19 (m, 1H), 0.89 (s, 9H), 0.04 (s, 6H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  127.04, 126.23, 67.95, 36.34, 28.23, 25.97, 25.70, 25.33, 24.78, 18.38, -5.32.

Synthesis of trans-1,2-dibromo-3-(*tert*-butyldimethylsilyloxymethyl)-cyclohexane (3). To a stirred solution of alkene (2) (1.81 g, 8 mmol) in  $\text{CCl}_4$  (15 mL) was added bromine (0.4  
30


5 mL, 8 mmol) in  $\text{CCl}_4$  (1 mL) dropwise. The resulting red mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (50 mL) and washed with 10%  $\text{Na}_2\text{S}_2\text{O}_3$  solution (50 mL) and water (50 mL). The organic phase was dried over  $\text{Na}_2\text{SO}_4$  and evaporated *in vacuo* to give 2.98 g (96%) of compound (3) as a yellow oil.  $R_f$  0.20 (100:1 hexane/EtOAc).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  4.71 - 4.64 (m, 2H), 3.47 (d,  $J$  = 5.3 Hz, 2H), 2.52 - 2.40 (m, 2H), 2.23 - 1.52 (m, 5H), 0.89 (s, 9H), 0.04 (s, 6H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  67.27, 53.60, 53.45, 34.23, 31.41, 28.12, 25.88, 23.25, 18.26, -5.39.

Synthesis of 5-hydroxymethylcyclohexa-1,3-diene (5). To stirred 0 °C solution of dibromide (3) (69.52 g, 0.18 mol) and Aliquat 336 (1.46 g, 3.6 mmol, 0.02 equiv) in THF (500 mL) was added KOtBu (44.89 g, 0.4 mol, 2.2 equiv). Immediate formation of a yellow precipitate occurred and after 5 minutes the cooling bath was removed. After 30 minutes, an aliquot of the mixture was removed and dried under a stream of argon.  $^1\text{H}$  NMR analysis ( $\text{C}_6\text{D}_6$ ) indicated that only a trace of dibromide (3) was remaining. After an additional 40 minutes, the mixture was evaporated *in vacuo*, diluted with hexane (300 mL) and washed with a saturated  $\text{NH}_4\text{Cl}$  solution (300 mL). After separation the aqueous layer was extracted with hexane (200 mL) and the combined organic layers were washed with water (300 mL), dried over  $\text{MgSO}_4$  and evaporated *in vacuo* to afford 65 g of crude diene (4). This material was dissolved in MeOH (600 mL) and treated with Dowex 50WX4-50 (65 g). The slurry was shaken at 200 rpm for 140 minutes after which time TLC indicated no remaining (4). The resin was filtered and washed with MeOH. The filtrate was evaporated *in vacuo* and the resulting residue was distilled bulb-to-bulb under reduced pressure to give diene (5) (16.71 g, 84%) as a colorless liquid. Bp 47 °C (2.2 mbar) – 50 °C (1.7 mbar);  $R_f$  0.49 (1:1 hexane/EtOAc).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  5.98 - 5.62 (m, 4 H), 3.58 (d,  $J$  = 5.9 Hz, 2 H), 2.56 - 2.42 (m, 1 H), 2.37 - 2.05 (m, 2 H), 1.50 (s, 1 H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  126.92, 125.39, 124.98, 123.63, 64.58, 35.47, 24.91.

5 Example 2. Preparation of NHS reagent (10)

Scheme 2 illustrates the preparation of NHS reagent (10) from diene (5).

Scheme 2



Synthesis of 13-N-(5-cyclohexa-1,3-dienemethoxycarbonyl)-4,7,10-trioxa-1,13-

- 10 tridecanediamine (8). To a stirred solution of diene (5) (1.10 g, 10 mmol) in THF (20 mL) was added 1,1'-carbonyldiimidazole (CDI) (1.63 g, 10.05 mmol). After 40 minutes, a solution of 4,7,10-trioxa-1,13-tridecanediamine (7) (4.4 mL, 20 mmol) in THF (5 mL) was added. After 50 minutes the reaction mixture was diluted with EtOAc (50 mL) and washed with brine (50 mL) and water (2x50 mL). The organic phases were combined,
- 15 dried over MgSO<sub>4</sub> and evaporated *in vacuo*. Purification via chromatography on the Biotage Flash 40 system eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/Et<sub>3</sub>N (15:1:0.1) afforded 2.62 g (74%) of carbamate (8) as a colorless oil. *R*<sub>f</sub> 0.48 (5:3:1 CHCl<sub>3</sub>/MeOH/AcOH, 32%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.94 - 5.82 (m 2 H), 5.74 - 5.69 (m, 1 H), 5.64 - 5.59 (m, 1 H), 5.50 (s, 1



5 H), 3.96 (d,  $J = 7.0$  Hz), 3.63 - 3.49 (m, 12 H), 3.25 (q,  $J = 6.5, 5.9$  Hz, 2 H), 2.76 (t,  $J = 6.7$  Hz, 2 H), 2.61 - 2.49 (m, 1 H), 2.28 - 2.18 (m, 1 H), 2.13 - 2.03 (m, 1 H), 1.78 - 1.65 (m, 4 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  156.20, 125.94, 124.68, 123.28, 69.90, 69.50, 68.79, 68.65, 65.25, 38.94 38.05, 32.50, 32.32, 28.90, 24.55.

10 Synthesis of 18-N-(5-cyclohexa-1,3-dienemethoxycarbonyl)-18-amino-5-aza-4-keto-9,12,15-trioxa-18-octadecanoic acid (9). To a solution of amine (8) (1.43 g, 4 mmol) and N-methylimidazole (NMI) (0.64 mL, 8 mmol) in pyridine (20 mL) was added succinic anhydride (0.44 g, 4.4 mmol). This mixture was stirred for 2 hours, evaporated *in vacuo* and the residue was purified by silica gel chromatography on the Biotage Flash 40 system  
15 eluting with  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{Et}_3\text{N}$  (10:1:0.1). To remove  $\text{Et}_3\text{N}$ , the product was dissolved in MeOH (20 mL) and treated with Dowex MWC-1 (2 g) for 1 hour. The solids were filtered and the filtrate was evaporated *in vacuo* to yield 1.50 g (82%) of acid (9) as slightly yellow oil.  $R_f$  0.64 (5:3:1  $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$ , 32%), 0.12 (10:1:0.1  $\text{CHCl}_3/\text{MeOH}/\text{Et}_3\text{N}$ ).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.15 - 6.98 (m, 1 H), 5.97 - 5.82 (m, 2 H), 5.77  
20 - 5.69 (m, 1 H), 5.65 - 5.60 (m, 1 H), 5.37 - 5.28 (m, 1 H), 3.98 (d,  $J = 7.0$  Hz, 2 H), 3.64 - 3.46 (m, 12 H), 3.31 (q,  $J = 6.5, 5.9$  Hz), 3.26 (q,  $J = 6.5, 5.9$  Hz), 2.61 - 2.51 (m, 3 H), 2.46 (t,  $J = 6.2$  Hz, 2 H), 2.33 - 2.20 (m, 1H), 2.18 - 2.02 (m, 1 H), 1.79 - 1.71 (m, 4 H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  175.46, 172.40, 156.69, 126.32, 125.21, 123.79, 70.29, 70.24, 69.86, 69.65, 69.23, 66.01, 38.71 37.80, 32.74, 30.89, 30.12, 29.32, 28.61, 25.02.

25

Synthesis of 18-N-(5-cyclohexa-1,3-dienemethoxycarbonyl)-18-amino-5-aza-4-keto-9,12,15-trioxa-18-octadecanoic acid N-hydroxysuccinimide ester (10). To a stirred 0 °C solution of acid (9) (913 mg, 2 mmol), N-hydroxysuccinimide (230 mg, 2 mmol) and DMAP (12 mg, 0.1 mmol) in  $\text{CH}_2\text{Cl}_2$  (10 mL) was added dicyclohexylcarbodiimide (433  
30 mg, 2.1 mmol). After 5 minutes the cooling bath was removed. After 2 hours, TLC indicated incomplete conversion and additional N-hydroxysuccinimide (46 mg, 0.4 mmol) and dicyclohexylcarbodiimide (83 mg, 0.4 mmol) were added. After 22 hours, TLC analysis still indicated incomplete conversion and more N-hydroxysuccinimide (46 mg, 0.4 mmol) and dicyclohexylcarbodiimide (83 mg, 0.4 mmol) were added. After 3 hours,  
35 the mixture was filtered through Celite and the precipitate was washed with  $\text{CH}_2\text{Cl}_2$  (10 mL). The filtrate was evaporated *in vacuo* and the residue was dissolved in EtOAc (5

5 mL), again filtered and evaporated *in vacuo*. Flash chromatographic purification employing the Biotage Flash 40 system eluting with a gradient of hexane/acetone 1:1 → 1:0.8 → 1:0.6 afforded 370 mg (33%) of NHS-ester (10) as a colorless oil.  $R_f$  0.45 (10:1:0.2 CHCl<sub>3</sub>/MeOH/AcOH), 0.32 (1:2 hexane/acetone). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.69, 6.52 (2s 1 H), 5.91 - 5.82 (m, 2 H), 5.73 - 5.69 (m, 1 H), 5.63 - 5.59 (m, 1 H), 5.25 (s, 1 H), 3.95 (d,  $J$  = 6.5 Hz, 1 H), 3.60 - 3.48 (m, 12 H), 3.34 - 3.30 (m, 2 H), 3.23 - 3.20 (m, 1 H), 2.97 - 2.90 (m, 2 H), 2.79 (s, 4 H), 2.73 - 2.50 (m, 3 H), 2.32 - 2.02 (m, 2 H), 1.75 - 1.71 (m, 4 H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 169.63, 168.94, 168.08, 156.47, 126.31, 125.16, 125.11, 123.70, 70.23, 70.20, 69.70, 69.77, 69.22, 65.85, 38.73, 37.92, 32.70, 30.25, 29.26, 28.53, 26.54, 25.36, 24.94.


15

### Example 3. Synthesis of Diene Phosphoramidite (16)

The synthesis of the diene-phosphoramidite (16), which is suitable for the attachment to the 5'-end of an oligonucleotide, is outlined in Scheme 3. Briefly, starting from the commercially available and enantiomerically pure alcohol (11) the universal linker (12) was obtained by LiAlH<sub>4</sub> reduction. The crude amine was acylated with diene-carbamate (6), generated *in situ* by the reaction of diene (5) with carbonyldiimidazole (CDI) as described in Example 1. The crude product, diol (13) was then acetylated to enable purification by flash-chromatography. After purification, the acetates were cleaved and the crude diol was selectively tritylated with 4,4'-dimethoxytrityl chloride (DMT) to give the alcohol (15). Alcohol (15) was then reacted with 2-cyanoethyl-bis-(N,N-diisopropylamino)-phosphoramidite and 4,5-dicyanoimidazole (DCI) to produce amidite (16), which was then purified by flash-chromatography.

26

## Scheme 3



10 Synthesis of (S)-5-amino-pentane-1,3-diol (12).  $\text{LiAlH}_4$  (26.5 g, 0.70 mol) was suspended in anhydrous THF (250 mL) and cooled to 0 °C. Alcohol (11) (20.0 g, 0.13 mol), dissolved in anhydrous THF (100 mL), was added dropwise. The mixture was warmed to room temperature and stirred overnight. After cooling to 0 °C, the mixture was treated sequentially with  $\text{H}_2\text{O}$  (12.6 mL, 0.70 mol), 10 N NaOH (34.9 mL, 0.35 mol) and  $\text{H}_2\text{O}$  (37.8 mL, 2.10 mol). The resulting solids were removed by filtration and the filtrate was concentrated *in vacuo*. The material recovered (12.7 g, 84%) was consistent with the desired amine-diol (12).

15 Synthesis of (S)-O-cyclohexa-2,4-dienylmethyl-N-(3,5-diacetoxypentyl)-carbamate (14).

Diene-carbamate (6) was generated *in situ* by addition of CDI (3.5 g, 21.6 mmol) to a solution of diene-alcohol (5) (2.0 g, 18.2 mmol) in DMF (17 mL). After stirring for 2 hours the crude amine (12) (2.0 g, 16.8 mmol) was added and stirring was continued overnight. The mixture was concentrated *in vacuo* and the residue dissolved in  $\text{CH}_2\text{Cl}_2$  (55 mL). After addition of  $\text{Et}_3\text{N}$  (23.4 mL, 168 mmol), the mixture was cooled to 0 °C and treated with  $\text{Ac}_2\text{O}$  (15.9 mL, 168 mmol). The solution was allowed to warm to room temperature and stirring was continued overnight. The reaction mixture was washed with a saturated  $\text{NaHCO}_3$  solution (50 mL) and brine (50 mL), dried over  $\text{Mg}_2\text{SO}_4$  and

5 concentrated *in vacuo*. The crude product was then purified by flash chromatography (Biotage Flash 40 system) on silica gel, eluting with EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (1:4 v/v) to yield 1.9 g (33%) of carbamate (14) as a colorless oil: *R<sub>f</sub>* 0.24 (EtOAc/CH<sub>2</sub>Cl<sub>2</sub> 1:4 v/v). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.97-5.62 (m, 4H), 5.10-5.00 (m, 2H), 4.12-3.97 (m, 4H), 3.40-3.34 (m, 2H), 3.02-2.94 (m, 2H), 2.67-2.58 (m, 2H), 2.67-2.58 (m, 1H), 2.30-1.64 (m, 8H). ES-  
10 MS (pos): [M + H]<sup>+</sup> 340 (339.2 calcd).

Synthesis of (S)-O-cyclohexa-2,4-dienylmethyl-N-[5-(4,4'-dimethoxytrityl)-3-hydroxypentyl]-carbamate (15). Diacetate (14) (1.9 g, 5.6 mmol) was dissolved in MeOH (30 mL) and K<sub>2</sub>CO<sub>3</sub> (39 mg, 0.3 mmol) was added. After 2 hours, the mixture was  
15 concentrated *in vacuo* and the residue was dried by azeotropic distillation with pyridine (2x20 mL). The crude diol was dissolved in pyridine (37 mL) and treated with 4,4'-dimethoxytrityl chloride (3.77 g, 11.1 mmol). The reaction was stirred overnight and then concentrated to a residue. The reddish oil was dissolved in EtOAc (50 mL) and washed sequentially with a saturated NaHCO<sub>3</sub> solution (50 mL) and brine (50 mL). The organic  
20 phase was dried over MgSO<sub>4</sub>, filtered and concentrated *in vacuo*. The crude residue was purified by flash chromatography (Biotage Flash 40 system) on silica gel, eluting with EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (1:9 v/v) to yield 1.0 g (32%) of alcohol (15) as a slightly yellow oil. *R<sub>f</sub>* 0.21 (EtOAc/CH<sub>2</sub>Cl<sub>2</sub> 1:9 v/v). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.42-7.15 (m, 8H), 6.85-6.82 (m, 4H), 5.97-5.85 (m, 2H), 5.77-5.62 (m, 2H), 5.20 (m, 1H), 4.04-3.99 (m, 2H),  
25 3.86-3.80 (m, 8H), 3.51-3.35 (m, 3H), 3.19-2.26 (m, 2H), 2.63 (m, 1H), 2.26-2.04 (m, 2H), 1.85-1.53 (m, 4H).


Synthesis of (S)-O-cyclohexa-2,4-dienylmethyl-N-{3-[(2-cyanoethoxy)-diisopropylaminophosphano]-5-(4,4'-dimethoxytrityl)}-3-hydroxypentyl]-carbamate (16).  
30 A solution of alcohol (15) (1.00 g, 1.8 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (18 mL) was treated with 2-cyanoethyl-bis-(N,N-diisopropylamino)-phosphoramidite (0.60 g, 2.0 mmol), followed by 4,5-dicyanoimidazole (0.11 g, 0.9 mmol). After stirring for 1 hour, TLC analysis indicated complete conversion of (15). The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed with a saturated NaHCO<sub>3</sub> solution (30 mL) and brine (30 mL), dried over  
35 MgSO<sub>4</sub> and concentrated *in vacuo*. The crude residue was purified by flash chromatography (Biotage Flash 40 system) on silica gel, eluting with EtOAc/CH<sub>2</sub>Cl<sub>2</sub> (1:9

5 v/v) to afford 933 mg (68%) of amidite (16) as a colorless foam.  $R_f$  0.40 (EtOAc/CH<sub>2</sub>Cl<sub>2</sub> 1:9 v/v). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.43-7.17 (m, 8H), 6.84-6.79 (m, 4H), 5.97-5.85 (m, 2H), 5.77-5.62 (m, 2H), 5.48 (m, 1H), 4.06-3.97 (m, 3H), 3.85-3.45 (m, 10H), 3.30-3.12 (m, 4H), 2.68-2.61 (m, 3H), 2.46-2.42 (m, 1H), 2.23-1.59 (m, 8H), 1.16-1.02 (m, 12H). <sup>31</sup>P NMR (121 MHz, CDCl<sub>3</sub>) 149.08, 148.38. ES-MS (pos): [M+H<sub>3</sub>O]<sup>+</sup> 776 (776.4 calcd).

#### Example 4. Synthesis of a Maleimide-Silane Reagent

Scheme 4 illustrates the synthesis of a maleimide-silane reagent for the functionalization of glass surfaces. Briefly, with reference to Scheme 4, propylaminosilane (17) was reacted with the functionalized maleimide N-hydroxysuccinimide-ester (18), to provide after aqueous work-up maleimide-silane (19), which was used as a crude product for derivatization of glass surfaces.

Scheme 4



20


Synthesis of 3-maleimido-N-(3-triethoxysilanylpropyl)-propionamide (19). 3-Maleimidopropionic acid N-hydroxysuccinimide ester (18) (4.0 g, 15.03 mmol, 1.0 equiv.) was dissolved in N,N-dimethylformamide (75 mL) and 3-aminopropyltriethoxysilane (17) (5.06 mL, 15.03 mmol, 1 equiv.) was added and the reaction mixture was allowed to stir for 22 hours. An aliquot (0.15 mL) was removed by syringe, concentrated *in vacuo*, and the resulting oil was analyzed by <sup>1</sup>H NMR spectroscopy. The oil was consistent with the desired product. The reaction mixture was then concentrated *in vacuo* at 50-55 °C and the residue obtained was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (75 mL), washed with water (3x50 mL) and brine (50 mL), filtered through granular Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure *in vacuo* to provide 6.65 g (>100% due to residual N,N-dimethylformamide) of the crude maleimide-silane (19) as a light yellow oil. Crude (19) was used without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.65 (s, 2H), 6.00 (s, 1H), 3.77 (q,  $J$  = 7 Hz, 6H), 3.70 (m, 2H), 3.17 (m, 2H), 2.46 (m, 2H), 1.56 (m, 2H), 1.18 (t,  $J$  = 7 Hz, 9H), 0.57 (m, 2H). <sup>13</sup>C NMR

- 5 (75 MHz,  $\text{CDCl}_3$ )  $\delta$  170.36, 169.28, 134.09, 58.35, 41.77, 34.56, 34.21, 23.20, 18.20, 7.65.  
 FB-MS (pos):  $[\text{M}+\text{H}]^+$  373 (373.2 calcd).

#### Example 5. Synthesis of a Diene-Silane Reagent

10 Scheme 5 illustrates the synthesis of a diene-silane reagent for the functionalization of glass surfaces. Briefly, with reference to Scheme 5, analogous to the synthesis of linker (13), diene (5) was treated with carbonyldiimidazole. To the imidazolate formed *in situ* was added amine (17). After stirring overnight the product of the reaction mixture, diene-silane (20) was separated and used as a crude product for glass surface functionalizations.

Scheme 5



#### 15 Synthesis of O-cyclohexa-2,4-dienylmethyl-N-(3-triethoxysilanylpropyl)-carbamate (20).

Diene alcohol (5) (0.50 g, 4.54 mmol, 1.0 equiv.) was dissolved in N,N-dimethylformamide (15 mL), carbonyldiimidazole (0.77 g, 4.77 mmol, 1.05 equiv.) was added and the mixture was allowed to stir for 4 hours. The formation of the imidazolate intermediate (6) (Scheme 2) was confirmed by <sup>1</sup>H NMR spectroscopic analysis of an aliquot (0.3 mL) of the reaction mixture that was concentrated *in vacuo* to an oil. The oil was consistent with desired intermediate by <sup>1</sup>H NMR spectroscopy as evidenced by the chemical shift in the resonance of the methylene protons from 3.6 ppm to 4.3 ppm. 3-Aminopropyltriethoxy silane (17) (1.51 mL, 4.50 mmol, 1.0 equiv.) was then added and the reaction mixture was stirred for 12 hours. The formation of the desired product (20) was confirmed by <sup>1</sup>H NMR spectroscopic analysis of an aliquot (0.3 mL) of the reaction mixture that was concentrated *in vacuo* to an oil. The oil was consistent with desired product as evidenced by the chemical shift in the resonance of the methylene protons from 4.3 ppm to 4.0 ppm. The reaction mixture was concentrated at reduced pressure, *in vacuo* overnight and imidazole crystallized out of the resulting brown oil. The oil obtained was separated from the crystals by pipette and transferred to a clean round-bottom flask to provide 1.5 g (93%) of the desired diene-silane (20) as a brown oil. Crude (20) was used without further purification. <sup>1</sup>H NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  5.98 – 5.63 (m, 4H), 4.95 (s, 1H), 4.00 (m, 2H), 3.82 (q, *J* = 7 Hz, 6H), 3.16 (m, 2H), 2.62 (m, 1H), 2.16 (m, 2H), 1.62

25  
30

- 5 (m, 2H), 1.23 (t,  $J = 7$  Hz, 9H), 0.64 (m, 2H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  158.67, 135.41, 126.70, 125.59, 124.14, 66.39, 58.66, 43.16, 33.15, 25.42, 23.85, 18.52, 7.81. FB-MS (pos):  $[\text{M}+\text{H}]^+$  358 (358.2 calcd).

Example 6. Synthesis of Labeled Oligonucleotides


- 10 The synthesis of various labeled and unlabeled (for control experiments) oligonucleotides is illustrated in Schemes 6 and 7 below. All syntheses were carried out employing standard procedures for solid phase oligonucleotide synthesis using phosphoramidite building blocks and a CPG solid support. The 20 mer (22) (SEQ ID NO:1) was chosen for purposes of illustration. With reference to Scheme 6, DNA
- 15 oligonucleotide (22) was synthesized on CPG performing the standard protocol to give the CPG bound oligonucleotide (21). An aliquot of (21) was deprotected and cleaved from the CPG support, to provide the crude control oligonucleotide (22). The diene labeled oligonucleotide (23) was synthesized by prolongation of the 5'-end of (21) with the diene-linker amidite (16). After further processing and detritylation/cleavage the crude
- 20 oligonucleotide was subjected to AX-HPLC to yield 86% of pure (23).

- In a second experiment, the diene-functionalized CPG bound oligonucleotide obtained from step c was divided into two portions. One portion was cleaved and deprotected without detritylation to give crude diene(DMT)-oligonucleotide (24) (Scheme 6) and the second portion was processed as described above, but without purification to
- 25 give crude diene-oligonucleotide (23).

31

## Scheme 6

5



Key: a: coupling; b: oxidation; c: capping; d: detritylation;  
e: deprotection and cleavage from CPG; f: purification

In order to perform the Diels-Alder cycloaddition in the reverse direction a maleimide functionalized oligonucleotide was synthesized as illustrated in Scheme 7. With reference to Scheme 7, the standard sequence was synthesized on a CPG support and extended with a protected amino-linker. Following deprotection and cleavage from the CPG support the 5'-amino-hexyloligonucleotide product (25) was acylated with the maleimide NHS-ester (18). Following filtration through Sephadex the crude maleimide-oligonucleotide (26) was obtained.


In order to allow fluorescence detection of the immobilized oligonucleotide by hybridization with a dye-labeled complementary sequence the 20 mer 5'-fluorescein-CACACACACACACACACA-3' (27) (SEQ ID NO:2) was synthesized on a CPG support employing the standard protocol.



32

## Scheme 7

5



Synthesis of 5'-TGTGTGTGTGTGTGTGTGTG-3' (22) (SEQ ID NO:1). The synthesis of oligonucleotide (22) was accomplished by the standard phosphoramidite method on a 8800 DNA/RNA synthesizer (Millipore) at 160  $\mu$ mol scale. After the final detritylation and subsequent washing, an aliquot of CPG bound oligonucleotide (21) was removed, dried and deprotected by 27% aqueous  $NH_4OH$  for 15 hours at 55  $^{\circ}C$ . Anion exchange HPLC analysis demonstrated a purity of 78% (at 260 nm) of crude oligonucleotide (22).

Synthesis 5'-diene-oligonucleotide (23). Synthesis of compound (23) was performed on a Millipore 8800 synthesizer in a fluidized bed conformation. The CPG bound oligonucleotide (21) (160  $\mu$ mol) as described above was treated with amidite (16) (0.2 M in  $CH_3CN$ , 2.5 equiv.) and 4,5-dicyanoimidazole (1.0 M in  $CH_3CN$ , 16 equiv.) for 10 minutes followed by a second amidite (16) addition (0.2 M in  $CH_3CN$ , 1.5 equiv.) together with 4,5-dicyanoimidazole (1.0 M in  $CH_3CN$ , 16 equiv.) for 10 minutes. The support bound oligonucleotide was oxidized with  $I_2$  in the presence of pyridine under standard conditions and detritylated by treatment with 10% dichloroacetic acid in  $CH_2Cl_2$ . Cleavage from the support and base deprotection was performed with 27% aqueous  $NH_4OH$  for 2 hours at 70  $^{\circ}C$ . The deprotection solutions were then cooled to 4  $^{\circ}C$  before the CPG was filtered and washed with DI water to recover the crude oligonucleotide product, compound (23).

An aliquot of the crude oligonucleotide product (800  $\mu$ L) was loaded onto a DNAPac PA-100 4x250 mm anion exchange column at a concentration of 10.6 mg/mL. The product was eluted with a linear elution gradient employing a two-buffer system, where buffer A is 25 mM Trizma/1 mM EDTA (Trizma-EDTA) with 10%  $CH_3CN$  and buffer B is Trizma-EDTA with 10%  $CH_3CN$  and 1 M NaCl. A temperature of 80 $^{\circ}C$  was maintained throughout the purification. Appropriate purification fractions were consolidated and

5 desalted on a Nap25 column. After desalting the oligonucleotide (23) (designated as "23, pure") was provided in deionized-water at a concentration of 1.1 OD/mL (86% purity by anion exchange HPLC). MALDI-MS:  $M^+$  6585.47 (6585.1 calcd).

In a second synthesis of oligonucleotide (23), CPG bound oligonucleotide (21) (25  $\mu$ mol) was treated with amidite (16) (0.2 M in  $\text{CH}_3\text{CN}$ , 15 equiv.) and 4,5-dicyanoimidazole (1.0 M in  $\text{CH}_3\text{CN}$ , 16 equiv.) for 20 minutes. After oxidation and capping the CPG bound oligonucleotide was partitioned into two aliquots. The first aliquot (0.25 g, 6  $\mu$ mol) was subjected to cleavage from the support and base deprotection to give 17 mg, (450 OD) of crude (purity 60% by anion exchange HPLC) diene (DMT)-oligonucleotide (24) after drying. The second aliquot (0.80 g, 19  $\mu$ mol) was detritylated prior to cleavage from the support and base deprotection to give 89 mg (2400 OD) of crude (61% purity by anion exchange HPLC purity) oligonucleotide (23) (designated as "23, crude").

Synthesis of 5'-[N-(3-maleimidopropionyl)-6-aminoheptyl]-TGTGTGTGTGTGTGTGTG  
 20 TG-3' DNA oligonucleotide (26). 2-Cyanoethyl-N,N'-diisopropyl-6-(4-methoxytrityl-amino)-hexylphosphoramidite\* (0.2 M in  $\text{CH}_3\text{CN}$ , 10 equiv. each. Proligo Biochemie GmbH, Hamburg, Germany. Prod.# M010282) was coupled to CPG bound oligonucleotide (21) (32  $\mu$ mole) in the presence of 4,5-dicyanomidazole activator (1.0 M in  $\text{CH}_3\text{CN}$ , 16 equiv.) for 20 minutes. Standard oxidation and capping preceded the final monomethoxytrityl removal with 10% dichloroacetic acid in  $\text{CH}_2\text{Cl}_2$ . Cleavage and deprotection of the oligonucleotide from the support in 27% aqueous  $\text{NH}_4\text{OH}$  and consequential drying provided 155 mg (4200 OD) of crude amino-oligonucleotide (25) (55% purity by anion exchange HPLC).

Amino-oligonucleotide (25) (2.6  $\mu$ mol) was resuspended in DMF (2 mL). To this solution maleimide NHS-ester (18) (35 mg, 130  $\mu$ mol, 50 equiv.) was added and the reaction was stirred at room temperature overnight then placed in speed vacuum to remove the solvent. The dried pellet was then resuspended in  $\text{H}_2\text{O}$  (1.5 mL) and loaded onto four 1 mL G-25 spin columns to remove un-reacted (18) and side products from the product of the reaction maleimide-oligonucleotide (26).

5 Detection of maleimide by fluorescence.

Maleimide-oligonucleotide (26) (15 nmol, ca. 500 OD) was reacted with deprotected 5-((2-and-3)-S-(acetylmercapto)succinoyl)amino)fluorescein (SAMSA fluorescein reagent). SAMSA fluorescein reagent was deprotected by addition of 0.1 M NaOH (50  $\mu$ L) to the protected SAMSA fluorescein reagent (500  $\mu$ g) and subsequent  
10 reaction at room temperature for 15 minutes followed by neutralization with 6 N HCl (0.7  $\mu$ L) buffered with 0.5 M  $\text{Na}_2\text{HPO}_4$ -buffer (10  $\mu$ L, pH = 7.0). The entire deprotected SAMSA-fluorescein was added to compound (26) (20  $\mu$ L, 15nmols) and incubated for 30 minutes at room temperature. Unreacted SAMSA-fluorescein was removed by loading of the reaction mixture on a 1 mL G-25 spin column, preequilibrated with phosphate-buffed  
15 saline. The product, fluorescein stained (26) (1,2 and 3  $\mu$ L) was loaded on a 15% polyacrylamide Tris borate EDTA (TBE) gel and scanned with the Typhoon Molecular Dynamics' Scanner for detection. Surface bound fluorescein was excited with a green laser followed by emission detection with a 526 nm filter (SP fluorescein filter). The photomultiplier tube settings were 600 V, sensitivity set to normal and the focal plane was  
20 set at the surface. The results are set forth in Figure 1. The presence of a fluorescent signal demonstrates that (25) was successfully reacted with reagent (18) to create the maleimide-oligonucleotide (26).


Synthesis of 5'-fluorescein-CACACACACACACACACA-3' DNA oligonucleotide  
25 (27) (SEQ ID NO:2). Two separate 1  $\mu$ mole syntheses were performed on an Expedite DNA/RNA synthesizer using the standard phosphoramidite protocol. 5' Fluorescein-phosphoramidite (0.1 M in  $\text{CH}_3\text{CN}$ , 11.2 equiv., available from Glen Research, VA, USA. Prod.# 10 5901) was coupled to the CPG-bound 20mer in the presence of tetrazole (0.25 M in  $\text{CH}_3\text{CN}$ , 102 equiv.) for 5 minutes. Deprotection in 27% aqueous  $\text{NH}_4\text{OH}$  resulted  
30 in approximately 300 OD of crude product for anion exchange HPLC purification. Purification utilizing a buffer system of 20 mM  $\text{NaClO}_4$  with 20 mM NaOAc and 10 vol-%  $\text{CH}_3\text{CN}$  (buffer A) and 600 mM  $\text{NaClO}_4$  with 20 mM NaOAc and 10% vol  $\text{CH}_3\text{CN}$  (buffer B), resulted in 75.7 OD of oligonucleotide product (27) from synthesis #1 (96.6% purity by anion exchange HPLC) and 79.3 OD of oligonucleotide product (27) from  
35 synthesis #2 (80% purity by anion exchange HPLC). Both oligonucleotides were desalted on Nap 10 columns and finally evaporated in a speedvac vacuum concentrator.

5

**Example 7. Functionalization of Glass Surfaces with Maleimide**


Scheme 8 illustrates the reaction of either glass slides or CPG with the maleimide-silane 19. The maleimide functionality is introduced onto the glass slides and CPG by condensation of maleimide-silane (19) with the glass surfaces.

10

**Scheme 8**

15

The method used to detect maleimide functionalization of the glass surfaces involves staining the glass surface with a thiol-containing fluorescein reagent, which reacts with the surface-bound maleimide via a Michael-addition reaction, as illustrated in Scheme 9. The presence of fluorescein bound to the surfaces can then be detected with a Molecular Dynamics' Typhoon fluorescence Scanner using a green laser to excite the surface-bound fluorescein followed by detection of emission using a 526nm filter.

**Scheme 9**

20

Pre-treatment of glass micro slides. Procedure #1: Glass micro slides (Corning no. 2947, description: plain, pre-cleaned, 3 inch x 1 inch x 1 millimeter) were soaked in 2 N NaOH for 2 hours at ambient temperature, washed with water, soaked in boiling 2 N HCl for 1 hour, washed with water and methanol, and then dried under reduced pressure in a high vacuum oven at 100° C for 2 hours. The slides were then allowed to cool in a vacuum

25

- 5 desiccator until use. Procedure #2: Micro slides were soaked in 2 N HCl at ambient temperature for 2 hours then in boiling 2 N HCl for 1 hour, washed with water and methanol, and then dried under reduced pressure in a high vacuum oven at 100 °C for 2 hours. The slides were then allowed to cool in a vacuum desiccator until use.
- 10 Maleimide functionalization of glass slides. The micro slides (2 pre-treated according to procedure #1 and 2 pre-treated according to procedure #2) were placed upright into a slide chamber containing a 1% (v/v) solution of the maleimide-silane reagent (19) in toluene (25 mL). The amount of solution used was sufficient to soak only the lower half (approximately 1.5 inches) of each slide. After 16 hours, one of the slides (pre-treated
- 15 according to procedure #1) was removed from the chamber and washed sequentially with toluene, methanol, methanol/water (1:1, v/v), water, methanol/water (1:1, v/v), methanol and ethyl acetate (both sides of the slide were washed with 3x2 mL of each solvent by pipette). The slide was then allowed to air dry.
- 20 Detection of surface-maleimide by fluorescence. The slide was assayed for maleimide functionalization using a thiol-containing fluorescein reagent, 5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino)fluorescein (SAMSA fluorescein, Molecular Probes). One side of the slide was completely covered with an activated solution of SAMSA fluorescein (prepared from 10 mg in 1 mL of 0.1 M NaOH, 14 µL of 6 M HCl, 0.2 mL of 0.5 M
- 25 sodiumphosphate buffer, pH = 7) and incubated at ambient temperature for 30 minutes. The slide was then soaked in 0.5 M sodium phosphate buffer, pH 7, for 30 minutes with agitation and blotted dry with a fine paper tissue. The slide was then placed on the surface of a Molecular Dynamics' Typhoon fluorescence scanner. Surface bound fluorescein was excited with a green laser followed by emission detection with a 526 nm filter (SP
- 30 fluorescein filter). The photomultiplier tube settings were 600 V, sensitivity set to normal and the focal plane was set at the surface.

The slide showed a strong response consistent with maleimide functionality primarily on the lower half of the slide (Figure 2). The distinct line and intense response at and below the halfway mark on the slide show that the maleimide functionalization of

35 the glass slide was successful. The slide also showed a weak response consistent with maleimide functionality on the edges of the slide, possibly due to the contact with the

5 sides of the chamber, and slightly above the halfway mark where the slide may have come in contact with the solution during addition or removal of the slide from the chamber. After 19 hours in the solution of toluene containing maleimide-silane reagent (19), the remaining slides were washed as described above and then treated with a 5 vol-% solution of chlorotrimethylsilane in pyridine/THF (1:9, v/v) for 5 minutes to cap free silanol  
10 groups. The slides were then washed with THF, methanol and ethyl acetate (both sides of the slide were washed with 3x2 mL of each solvent by pipette), allowed to air dry and were stored in the vacuum desiccator until use.

Pre-treatment of native CPG-500. Native CPG-500 was stirred in boiling 2 N HCl for 2  
15 hours, then collected on a glass-fritted funnel, washed with water and methanol, and dried under reduced pressure in a high vacuum oven at 100 °C for 2 hours. The CPG was then allowed to cool in a vacuum desiccator until use.

Maleimide functionalization of CPG. CPG (0.75 g, pre-treated according to the procedure  
20 described above) was stirred in a 1 vol-% solution of the maleimide-silane reagent (19) in toluene (25 mL) for 51 hours. The CPG was then collected on a glass-fritted funnel and washed sequentially with toluene, methanol, methanol/water (1:1, v/v), water, methanol/water (1:1, v/v), methanol and ethyl acetate (3x10 mL of each solvent). The powder was then treated with a 5 vol-% solution of chlorotrimethylsilane in pyridine/THF  
25 (1:9, v/v) for 2 minutes to cap free silanol groups. The CPG was then washed with THF, methanol and ethyl acetate (3x10 mL of each solvent). The powder was allowed to air dry in the funnel under suction for 5 minutes, transferred to a beaker and placed in a vacuum desiccator for 44 hours. The light tan powder (0.6 g) was then stored in a -20 °C freezer until use.


30  
Detection of surface maleimide by fluorescence. The derivatized CPG was assayed for maleimide functionalization using the thiol-containing fluorescein reagent, 5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino)fluorescein (SAMSA fluorescein). The CPG (5 mg) was placed into a centrifuge tube, an activated solution of SAMSA fluorescein (0.5 mL)  
35 was added, the vial was shaken to mix the contents and then allowed to sit at ambient temperature for 30 minutes. Native CPG-500 (5 mg) was also placed into a centrifuge

5 tube and treated with an activated solution of SAMSA fluorescein (prepared from 5 mg in 0.5 mL of 0.1 M NaOH, 7  $\mu$ L of 6 M HCl, 0.1 mL of 0.5 M sodiumphosphate buffer, pH = 7) following the same procedure to serve as a control. After 30 minutes, the mixtures were centrifuged, the supernatants were removed by pipette, and the CPG samples were suspended in water. The resulting mixtures were centrifuged, the supernatants again removed by pipette, and the CPG samples resuspended in water. This procedure was repeated until the supernatants were clear and colorless (total of 5 washes for each sample). Each powder was dispersed onto a clean sheet of plastic wrap that was folded to contain the powder. Both samples were then placed side by side on the surface of a Molecular Dynamics' Typhoon fluorescence scanner. Surface bound fluorescein was excited with a green laser followed by emission detection with a 526 nm filter (SP fluorescein filter). The photomultiplier tube settings were 600 V, sensitivity set to normal and the focal plane was set at the surface. The CPG that was treated with maleimide-silane showed a strong response consistent with maleimide functionality, whereas the native CPG-500 control did not show a response (Figure 3). The intense response on the CPG treated with the maleimide-silane versus the native CPG-500 control shows that the maleimide functionalization of the CPG was successful.

#### Example 8. Functionalization of Glass Surfaces with a Diene

Scheme 10 illustrates the functionalization of glass slides and CPG with diene-silane (20) to provide support-bound dienes capable of undergoing Diels-Alder surface immobilization of dienophiles. The diene functionality is introduced onto the glass slides and CPG by condensation of diene-silane (20) with the glass surfaces as shown in Scheme 10.


Scheme 10



5 The method used to detect diene functionalized glass surfaces involves staining the glass surfaces with a maleimide-containing fluorescein reagent, which reacts with the surface-bound diene via a Diels-Alder addition reaction as illustrated in Scheme 11. The presence of fluorescein bound to the surface can then be detected with a Molecular Dynamics' Typhoon fluorescence scanner using a green laser to excite the surface-bound

10 fluorescein followed by detection of emission using a 526 nm filter.

Scheme 11



Functionalization of glass slides with diene-silane reagent (20). Glass micro slides (4), pre-treated according to procedure #1 described in Example 7) were placed upright into a slide chamber containing a 1 vol-% solution of the diene-silane reagent (20) in toluene (25 mL). The amount of solution used was sufficient to soak only the lower half

15 (approximately 1.5 inch) of each slide. After 15 hours, a "T" was etched into the top, right-hand corner of each slide as it was removed from the chamber. The slides were washed sequentially with toluene, methanol, methanol/water (1:1, v/v), water,

20 methanol/water (1:1, v/v), methanol and ethyl acetate (both sides of each slide were washed with toluene (3x2 mL) by pipette and the remaining washes were done by soaking the slides in a petri dish containing 10 mL of the solvent). The slides were then allowed to air dry and were treated with a 5 vol-% solution of chlorotrimethylsilane in pyridine/THF (1:9, v/v) for 2 minutes to cap free silanol groups. The slides were then washed with THF,

25 methanol and ethyl acetate (both sides of the slide were washed with 3x2 mL of each solvent by pipette), allowed to air dry and were stored in the vacuum desiccator until use.

Detection of surface diene by fluorescence. One of the slides was assayed for diene functionalization using fluorescein-5-maleimide (Molecular Probes). Briefly, one side of



5 the slide was completely covered with a 10 mM solution of fluorescein-5-maleimide in N,N-dimethylformamide and incubated at 6 °C overnight. The slide was then washed with water (4x10 mL) and blotted dry with a fine paper tissue. The slide was then placed on the surface of a Molecular Dynamics' Typhoon fluorescence scanner. Surface bound fluorescein was excited with a green laser followed by emission detection with a 526 nm  
10 filter (SP fluorescein filter). The photomultiplier tube settings were 600 V, sensitivity set to normal and the focal plane was set at the surface. The slide showed a strong response consistent with diene functionality on the lower half of the slide (Figure 4). The distinct line and intense response at and below the halfway mark on the slide show that the diene functionalization of the glass slide was successful.

15

Diene functionalization of CPG. CPG (0.75 g, pre-treated according to the procedure described in Example 7) was stirred in a 1 vol-% solution of the diene-silane reagent (20) in toluene (25 mL) for 52 hours. The CPG was then collected on a glass-fritted funnel and washed sequentially with toluene, methanol, methanol/water (1:1, v/v), water,  
20 methanol/water (1:1, v/v), methanol and ethyl acetate (3x10 mL of each solvent). The powder was then treated with a 5 vol-% solution of chlorotrimethylsilane in pyridine/THF (1:9, v/v) for 2 minutes to cap free silanol groups. The CPG was then washed with THF, methanol and ethyl acetate (3x10 mL of each solvent). The powder was allowed to air dry in the funnel under suction for 5 minutes, transferred to a beaker and placed in a vacuum  
25 desiccator for 44 hours. The white powder (0.6 g) was then stored in a -20 °C freezer until use.


Detection of surface diene by fluorescence. The derivatized CPG was assayed for diene functionalization using fluorescein-5-maleimide (Molecular Probes). The CPG (5 mg)  
30 was placed into a centrifuge tube, a 10 mM solution of fluorescein-5-maleimide in DMF (0.5 mL) was added, the vial was shaken to mix the contents and incubated at 6 °C overnight. The mixture was then centrifuged, the supernatant was removed by pipette, and the CPG sample was suspended in water. The resulting mixture was centrifuged, the supernatant again removed by pipette, and the CPG sample resuspended in water. This  
35 procedure was repeated until the supernatant was clear and colorless (total of 5 washes). The powder was dispersed onto a clean sheet of plastic wrap that was folded to contain the

- 5 powder. Native CPG-500 (5 mg) was also treated with fluorescein-5-maleimide to serve as a control. It was incubated in a 10 mM solution of fluorescein-5-maleimide in DMF (0.5 mL) for 2 hours at ambient temperature and then treated according to the procedure described above for the CPG treated with the diene-silane. Both samples were then placed side by side on the surface of a Molecular Dynamics' Typhoon fluorescence scanner.
- 10 Surface bound fluorescein was excited with a green laser followed by emission detection with a 526 nm filter (SP fluorescein filter). The photomultiplier tube settings were 600 V, sensitivity set to normal and the focal plane was set at the surface. The CPG that was treated with diene-silane showed a strong response consistent with diene functionality (Figure 5A), whereas the native CPG-500 control did not show a response (Figure 5B).
- 15 The intense response on the CPG treated with the diene-silane versus the native CPG-500 control show that the diene functionalization of the CPG was successful.

#### Example 9. Immobilization of Oligonucleotides via Diels-Alder Cycloaddition

- 20 Scheme 12 illustrates the conjugation of diene oligonucleotide (23) to maleimide functionalized glass slides and maleimide coated microtiter plates. The demonstration of conjugation was achieved by hybridization with a labeled complementary sequence and the detection of fluorescence.

Scheme 12



5 Conjugation of diene-oligonucleotide (23) to maleimide functionalized glass slides. Two maleimide coated slides (1 pre-treated according to procedure #1 and 1 pre-treated according procedure #2, as described in Example 7) were each equipped with 3 silicone rubber septa (standard taper 14/20) running linearly up the slides using plastic ties to firmly secure the septa to the slides. Two septa were affixed to the lower maleimide-  
10 functionalized half of each slide and one septum was affixed to the upper non-functionalized half of each slide. The outline of the septa was etched into the slide that was pre-treated according to procedure #2. A 4 pmol/ $\mu$ L solution of 5'-diene-oligonucleotide (23), pure, in 100 mM  $\text{Na}_2\text{HPO}_4$  buffer at pH = 6.5 (125  $\mu$ L) was added to the septum placed at the bottom of each slide to demonstrate surface immobilization of an  
15 oligonucleotide on micro slides. (Figure 6). A 4 pmol/ $\mu$ L solution of control oligonucleotide (22) (SEQ ID NO:1) in 100 mM  $\text{Na}_2\text{HPO}_4$  buffer at pH = 6.5 (125  $\mu$ L) was added to the septum placed in the middle of each slide as a control to check for potential non-specific binding of the oligonucleotide to the functionalized portion of the slide. A 4 pmol/ $\mu$ L solution of 5'-diene-oligonucleotide (23), pure, in 100 mM  $\text{Na}_2\text{HPO}_4$   
20 buffer at pH = 6.5 (125  $\mu$ L) was added to the septum placed at the top of each slide as a control to check for potential non-specific binding of the (23) to the non-functionalized portion of the slides. The slides were incubated for 1 hour at 37 °C and then the septa were removed and the slides were soaked 3 times each in a petri dish containing TRIS-buffered saline containing Tween® 20 (TBST) (10 mM TRIS-Cl, pH 8, 150 mM NaCl,  
25 0.1% Tween® 20).

Detection of oligonucleotide immobilization on glass slides. The slides, pulled from the buffer solutions, were immediately (to prevent the slides from drying out) immersed in a 4 pmol/ $\mu$ L solution of complementary 5'-fluorescein-oligonucleotide (27) in 5X standard  
30 saline citrate (SSC) containing 0.1% sodium dodecyl sulfate (SDS) (750 mM NaCl, 75 mM Na citrate, pH = 7, 0.1% SDS) in a petri dish (ca. 10 mL). The slides were incubated for 30 minutes at 55 °C and were then soaked 3 times each in a petri dish containing TBST. The slides were then placed on the surface of a Molecular Dynamics' Typhoon fluorescence scanner. The fluorescein was excited with a green laser followed by  
35 emission detection with a 526 nm filter (SP fluorescein filter). The photomultiplier tube settings were 800 V, sensitivity was normal, and the focal plane was set at the surface. The

5 slides each showed a strong response where diene-oligonucleotide (23) came into contact with the maleimide-functionalized portion of the glass slide (27) (Figure 7). The two controls on each slide showed no response indicating the lack of non-specific binding of (22) to the maleimide-functionalized portion of the slide and the lack of non-specific binding of (23) to the non-functionalized portion of the slide. The outlines of the septa  
10 etched on the slide pre-treated according to procedure #2 (slide "2") are faintly visible in the scan.

Conjugation of diene-oligonucleotide (23) to maleimide coated microtiter plates. 200  $\mu$ L of either the 5'-diene-oligonucleotide (23), crude and pure, or control oligonucleotide (22)  
15 were added to maleimide microtiter plates (Pierce Cat # 15150ZZ) at a concentration of 2.5 pmol/ $\mu$ L in 100 mM  $\text{Na}_2\text{HPO}_4$  buffer at pH = 5.5, 6.5 or 7.7 as indicated. A well containing only 100 mM pH = 6.5  $\text{Na}_2\text{HPO}_4$  was also included as a control for non-specific binding of labeled complementary oligonucleotide (27). For conjugation via Diels-Alder reaction the plates were incubated for 2 hours at 37 °C. Wells containing the  
20 immobilized oligonucleotides were aspirated and washed 3 times with TBST (10 mM Tris-Cl pH = 8.0, 150 mM NaCl, 0.1% Tween 20).


Detection of oligonucleotide immobilization on maleimide coated microtiter plates. Equal molar amounts of labeled complementary oligonucleotide (27) were added to the wells in  
25 5 x SSC + 0.1% SDS (750 mM NaCl, 75 mM Na Citrate, pH = 7.0) and hybridized at 55 °C for 30 minutes. Following hybridization all samples were washed with TBST (3x200 mL). Plates and slides were placed on the surface of a Molecular Dynamics Typhoon fluorescence scanner and the fluorescein was excited with a green laser followed by emission detection with a 526 nm filter (SP fluorescein filter). Photomultiplier tube  
30 settings were 800 V, sensitivity was set to normal and the focal plane was set at the surface. Oligonucleotide immobilization was most efficient at pH = 6.5 as shown in Figure 8. The control oligonucleotide (22) set of reactions showed no non-specific binding as did all the buffer controls. The maleimide functionalized slide also demonstrates oligonucleotide immobilization as evident from the signal generated only  
35 from the area on the slide that was reacted with the silane-maleimide reagent (19).

5 Example 10. Conjugation of 5'-Diene-Oligonucleotide (24) to Maleimide functionalized CPG

Maleimide-CPG was incubated with oligonucleotide (24) to form the Diels-Alder adduct as illustrated in Scheme 13. Immobilization was verified by photometric determination of DMT after cleavage with acid.

10

Scheme 13



Titration of maleimide functionalized CPG with 5'-diene-oligonucleotide (24). A series of increasing amounts of diene(DMT)-oligonucleotide (24) (see Table 2) in Na<sub>2</sub>HPO<sub>4</sub> buffer (100 mM, pH = 6.5, 350  $\mu$ L) was added to maleimide derivatized CPG (10 mg, each), weighed each in centrifuge tubes. The mixtures were incubated at 37°C for 1 hour under shaking (to keep an optimal mixing of CPG). Each of the mixtures was centrifuged and the supernatant was removed by pipette. The CPG samples were suspended in water (1 mL) and the resulting mixtures were centrifuged and the supernatants again removed by pipette. This washing procedure was repeated three times for each sample before drying in a speed vacuum concentrator. The results of this titration are depicted graphically in Figure 9.

Time dependence of reaction between maleimide-CPG and diene(DMT)-oligonucleotide (24). Six samples were prepared by addition of diene(DMT)-oligonucleotide (24) (37 nmol) to each of 6 tubes containing a solution of maleimide derivatized CPG (10 mg, each) in Na<sub>2</sub>HPO<sub>4</sub> buffer (100 mM, pH = 6.5, 100  $\mu$ L), that had been pre-equilibrated at

- 5 37°C. The conjugation reaction was stopped after different time intervals (see Table 3) by removal of supernatant solution of (24) and washing of the CPG as described above. The results are depicted graphically in Figure 10.

- 10 Loading Determination. To each CPG containing tube a 3% solution of p-toluenesulfonic acid in CH<sub>3</sub>CN (0.75 mL) was added and the resulting mixture was agitated for 1 minute. For determination of loading the absorbance @ 497 nm of the supernatant was determined photometrically using the following equation:

$$L = \frac{V \cdot \text{ABS}}{m_{\text{resin}} \cdot \epsilon \cdot d}$$

$$V = 1 \text{ cm}^3$$

$$m_{\text{resin}} = 10 \text{ mg}$$

$$\epsilon = 71,200 \text{ cm}^2/\text{mmol}$$


$$d = 1 \text{ cm}$$

$$L [\text{umol/g}] = 1.4045 \cdot \text{ABS}$$

- 15 Example 11. Conjugation of 5'-Maleimide-Oligonucleotide (26) to Diene coated Glass Surfaces

- Scheme 14 shows the conjugation of maleimide-oligonucleotide (26) with diene functionalized glass surfaces. The demonstration of conjugation was achieved by hybridization with the labeled complementary sequence (27) and the detection of
- 20 fluorescence as described above.

Scheme 14



5 Conjugation of maleimide-oligonucleotide (26) to diene-functionalized glass slides. One diene-coated slide was equipped with 3 silicone rubber septa (standard taper 14/20) running linearly up the slide. The septa were compressed onto the slide between two 3 x 5 x ¼ inch pieces of acrylic sheet that were fastened together on both sides of the slide using thumb screws. The upper acrylic sheet contained 3/16-inch holes directly above the  
10 middle of the septa to allow needle-access to the septa. Two septa were affixed to the lower diene-functionalized half of the slide and one septum was affixed to the upper non-functionalized half of the slide. A 4 pmol/µL solution of maleimide-oligonucleotide (26) in 100 mM Na<sub>2</sub>HPO<sub>4</sub> buffer at pH = 6.5 (125 µL) was added to the septum placed at the bottom of the slide to demonstrate surface immobilization of an oligonucleotide on a  
15 micro slide. A 4 pmol/µL solution of control oligonucleotide (22) in 100 mM Na<sub>2</sub>HPO<sub>4</sub> buffer at pH = 6.5 (125 µL) was added to the septum placed in the middle of the slide as a control to check for potential non-specific binding of the oligonucleotide to the functionalized portion of the slide. A 4 pmol/µL solution of maleimide-oligonucleotide (26) in 100 mM Na<sub>2</sub>HPO<sub>4</sub> buffer at pH = 6.5 (125 µL) was added to the septum placed at  
20 the top of each slide as a control to check for potential non-specific binding of the maleimide-oligonucleotide (26) to the non-functionalized portion of the slide. The slide was incubated for 1 hour at 37 °C and then the septa were removed and the slide was soaked 3 times each in a petri dish containing TRIS-buffered saline containing Tween® 20 (TBST) (10mM TRIS-Cl, pH = 8, 150 mM NaCl, 0.1% Tween® 20).

25

Detection of oligonucleotide immobilization on glass slides. The slide, pulled from the buffer solution, was immediately (to prevent the slide from drying out) immersed in a 4 pmol/µL solution of complementary 5'-fluorescein-oligonucleotide (27) in 5X SSC containing 0.1% SDS (10 mL) in a petri dish. The slide was incubated for 30 minutes at  
30 55-60 °C. The slide was then soaked 3 times each in a petri dish containing TBST. The slide was analyzed using the Molecular Dynamics Typhoon fluorescence scanner, but the results indicated that the washing conditions were insufficient to remove non-specifically bound oligonucleotide from the plate (Figure 11, slide "1"). The slide was then washed 3 times in a petri dish containing 1X PBS (phosphate-buffered saline solution) with 0.1%  
35 SDS. The slide was again analyzed using the Molecular Dynamics Typhoon fluorescence scanner and showed a strong response only where maleimide-oligonucleotide (26) came

5 into contact with the diene-functionalized portion of the glass slide and then hybridized with (27) (Figure 11, slide "2"). The two controls on the slide showed no response indicating that the washing conditions were sufficiently stringent to remove non-covalently bound oligonucleotide (22) from the diene-functionalized portion of the slide and non-covalently bound maleimide-oligonucleotide (26) from the non-functionalized  
10 portion of the slide. The diene-functionalized portion of the slide (lower half) shows some fluorescence outside of the area that was reacted with (26) indicating there is some residual non-specific binding of (27) to the diene-functionalized portion of the slide.

Conjugation of maleimide-oligonucleotide (26) to diene-functionalized CPG. Diene-coated CPG (15 mg) was placed into a centrifuge tube. A 4 pmol/  $\mu\text{L}$  solution of  
15 maleimide-oligonucleotide (26) in 100 mM  $\text{Na}_2\text{HPO}_4$  buffer at pH = 6.5 (125  $\mu\text{L}$ ) was added, the vial was shaken to mix the contents, and then incubated for 1 hour at 37 °C. The mixture was then centrifuged, the supernatant was removed by pipette, and the CPG sample was suspended in TRIS-buffered saline containing Tween® 20 (TBST) (10 mM  
20 TRIS-Cl, pH = 8, 150  $\mu\text{M}$  NaCl, 0.1% Tween® 20). The resulting mixture was centrifuged, the supernatant again removed by pipette, and the CPG sample resuspended in TBST. This procedure was repeated for a total of 3 washes. In addition, two control experiments were run following the above procedure. One of the control experiments involved using control oligonucleotide (22) in place of compound (26) to check for  
25 potential non-specific binding of the oligonucleotide to diene-functionalized CPG. The other control experiment involved using non-functionalized CPG capped with chlorotrimethylsilane as a control to check for potential non-specific binding of the maleimide-oligonucleotide (26) to non-functionalized CPG.

30 Detection of oligonucleotide immobilization on CPG. A 4 pmol/ $\mu\text{L}$  solution of complementary 5'-fluorescein-oligonucleotide (27) in 5X SSC containing 0.1% SDS (125  $\mu\text{L}$ ) was immediately added to each of the CPG samples obtained after reaction with maleimide-oligonucleotide (26) and washings. The samples were incubated for 30 minutes at 55-60 °C. The samples were then washed 3 times as described above with 1X  
35 PBS (phosphate-buffered saline solution) with 0.1% SDS. After the final wash was removed by pipette, each sample was dispersed onto a clean sheet of plastic wrap and the




5 plastic wrap was folded to contain the powder. The three samples, individually wrapped, were then placed side-by-side on the surface of a Molecular Dynamics' Typhoon fluorescence scanner. The samples were analyzed using the Typhoon fluorescence scanner, but the results indicated that the washing conditions were insufficient to remove non-specifically bound (26) from the diene-functionalized CPG (Figure 12A). The samples were then transferred back into their original centrifuge tubes and washed 3 times with 0.5X SSC + 0.1% SDS (significant loss of each sample occurred during transfers). The samples were then again dispersed onto sheets of plastic wrap and analyzed using the Typhoon fluorescence scanner. The diene-functionalized CPG sample that was treated with maleimide-oligonucleotide (26) showed a strong response after hybridization with 27 (Figure 12B, slide "2A"). The two controls showed comparatively little response indicating that the Diels-Alder surface immobilization of maleimide-oligonucleotides can be performed on diene-functionalized CPG.

#### Example 12. Preparation of a Diene Modified Oligonucleotide

20 Scheme 15 illustrates the preparation of diene modified oligonucleotide (29) from N-hydroxysuccinimide ester (10), the synthesis of which is described in Example 2.

Scheme 15



25

5'-Amine modified oligodeoxynucleotide (28) (ODN99225) was prepared employing standard solid phase automated synthesis on controlled pore glass (CPG) via the phosphoramidite method. After deprotection and cleavage from the CPG support, the crude amine-modified oligonucleotide was purified by preparative anion exchange


5 chromatography on a 200 mL Source 15Q column (quaternary ammonium functionalized, monodisperse polystyrene beads) eluting with the gradient set forth in Table 4.

Product containing fractions were combined and concentrated *in vacuo*. The material was desalted by a HPLC-method which involved adsorbing the crude material onto a C18 column in water, washing with a 1 M NaCl solution followed by water, then  
 10 eluting the material with EtOH. The amine oligonucleotide was coupled to N-hydroxysuccinimide ester (10) in a mixture of 25 mM sodium borate buffer and acetonitrile (40%) employing roughly 4 equivalents of compound (10). Analytical reversed phase chromatography indicated a final product purity of 95.9%. Electrospray mass spectrometric analysis confirmed the identity of the oligonucleotide conjugate (29)  
 15 (observed MW=6639.0; calcd MW=6639).

Example 13. HPLC Monitoring of a Diels-Alder Reaction Employing a Cyclohexadiene Oligonucleotide

To confirm the Diels-Alder reactivity of diene conjugate (29), labeling with  
 20 commercially available maleimide dienophiles (30) (Aldrich) and (31) (Molecular Biosciences) were carried out as illustrated in Scheme 16. Briefly, to a solution of (29) (1.5 mM) in phosphate buffer (pH=6.8) were added 100 equivalents of compound (30) or (31). The progress of the reaction was monitored by analytical anion exchange chromatography with samples taken every 5 minutes (as described below). Treatment of  
 25 (29) with N-ethyl maleimide (30) resulted complete conversion to adduct (32) within 5 minutes, while biotin maleimide 31 required 20 minutes.

Scheme 16



The progress of the Diels Alder reaction was monitored as follows: 2  $\mu$ L of  
 30 reaction solution was removed, treated with 8  $\mu$ L of 0.1 M NaOH (to quench the


50

5 maleimide), vortexed for 30 seconds and diluted with 50  $\mu\text{L}$  of  $\text{H}_2\text{O}$ . Of this 60  $\mu\text{L}$  solution, 50  $\mu\text{L}$  ( $\sim 16.7$   $\mu\text{g}$  of oligonucleotide) was injected onto a 5 micron C18 Jupiter column. The samples were run using a buffer system of TEAA (pH 7.0; Eluent A) and acetonitrile (Eluent B) as outlined in Table 5.

10 Example 14. Preparation of diene modified polyethylene glycol substrates.

Scheme 17 illustrates the synthesis of a cyclohexadiene-PEG (34).


Scheme 17



Diene (10) was treated sequentially with carbonyldiimidazole and methoxy  
 15 polyethylene glycol amine (MW=5000). The resulting carbamate product was purified by  
 careful dropwise addition into cold ether and collection of the precipitate by filtration.  
 The material obtained was used without further purification in surface immobilization  
 studies. Similarly, hydroxymethylanthracene (35) was converted to the analogous PEG  
 derivative (36) using the same method as illustrated in Scheme 18.

20


Scheme 18



5 Example 15. Preparation of a Maleimide-Coated Flow Cell for the BIAcore

Scheme 19 illustrates the preparation of a dienophile derivatized CM5 BIAcore flow cell surface.

Scheme 19



10 The dienophile CM5 BIAcore flow cell surface was prepared by subjecting the commercially available chip (coated with a matrix of carboxymethyl dextran) to a 3 step derivatization procedure, as illustrated in Scheme 19. Briefly, the carboxy groups were activated as the N-hydroxysuccinimide esters (via treatment with EDC/NHS), followed by the addition of diamine linker (ethylene diamine, to provide a reactive primary amine surface), which was treated with a commercially available bifunctional crosslinking reagent. The resulting dienophile cell surface (37) was reproducibly prepared in this manner as evidenced by the measurement of the Biacore sensorgram with each experiment.

20 The sensorgrams were obtained using a BIAcore 2000 instrument (Pharmacia Biosensor AB, Uppsala, Sweden. Lofas *et al.* (1991) *Sens. Actuators B* 5:79-84; Malmqvist (1993) *Nature* 361:186-187.) employing a biosensor technique called "real-time biomolecular interaction analysis" (BIA), which allows the real-time monitoring of interactions between two or more molecules, such as proteins or nucleic acids and small molecules, such as signaling substances and pharmaceuticals (Pharmacia Biosensor AB, cf. <http://www.biacore.com>). The detection principle relies on the optical phenomenon of "surface plasmon resonance" (SPR), which detects changes in the refractive index of the solution close to the surface of the sensor chip (Brockman *et al.* (1999) *J. Am. Chem. Soc.* 121:8044-8051 and references cited therein). This is in turn directly related to the concentration of solute in the surface layer. To perform a BIA analysis, one interactant is

30 immobilized in a dextran matrix on the sensor chip, which forms one wall of a micro-flow cell. Sample containing the other interactant(s) is then injected over the surface in a

5 controlled flow. Any change in surface concentration resulting from interaction is detected as an SPR signal, expressed in resonance units (RU). The continuous display of RU as a function of time, referred to as a Biacore sensorgram, thus provides a complete record of the progress of association and dissociation.

Maleimide derivatization protocol (Khilko (1993) J. Bio. Chem. 268:15425-

10 15434):


Flow rate = 10  $\mu$ L/min with pH 6.8 PBS running buffer

**Injection sequence:**

1. 40  $\mu$ L of EDC-NHS mixture (from stock solutions: NHS at 11.5 mg/mL and EDC at 75 mg/mL).
- 15 2. 100  $\mu$ L of 1.0 M ethylenediamine diHCl at pH 6.0.
3. 100  $\mu$ L of 25 mM sulfo-EMCS (NHS/maleimide bifunctional reagent in pH 6.8 running buffer. The overlaid Biacore sensorgrams depicted in Figure 13 show the consistent results of this method.

20 Example 16. Comparison of Surface Derivatization via PEG-SH (Michael addition) vs PEG-Diene (Diels-Alder Surface Immobilization)

**Scheme 20**



25 By subjecting the dienophile flow cell surface described in Example 15 to MeO-PEG-SH (MW=5000; pH=6.8 phosphate buffer, 10  $\mu$ L/min flow rate), the functional activity of the surface was confirmed as evidenced by the Biacore sensorgram depicted in Figure 14.


Likewise, addition of the PEG-diene substrate (34) prepared in Example 14  
 30 afforded the Biacore sensorgram depicted in Figure 15, confirming the dienophile

- 5 reactivity of the flow cell surface and suggesting that the relative rate of the Diels-Alder surface immobilization is substantially slower than the Michael addition method employing a PEG-thiol (12 hours vs 10 minutes).

Example 17. BIAcore Diels-Alder Reaction with Anthracene-PEG (36)

10

Scheme 21




- Reaction of dienophile derivatized CM5 BIAcore flow cell surface (37) with the anthracene derivative (36) (preparation described in Example 14), using the method described in Example 16, provided compound (38), which is described in the literature to have improved aqueous Diels-Alder reaction kinetics. Enhanced surface immobilization was observed using compound (36), compared to compound (34). As can be seen Figure 16, a comparable response was observed in approximately half the time.

20 Example 18. BIAcore Surface Immobilization of Diene Modified Oligonucleotide (29) via the Diels-Alder Conjugation and Hybridization with the Complementary Sequence

- Surface immobilization of the cyclohexadiene modified oligonucleotide (29), followed by hybridization with the complementary oligonucleotide sequence is illustrated in Scheme 22. Briefly, the Diels-Alder reaction between dienophile (37) and diene (29) was carried out using the method described in Example 16 to provide the immobilized oligonucleotide, compound (39). The sensorgram results are set forth in Figure 17. Immobilized oligonucleotide (39) was then hybridized with its complementary sequence using standard means. The BIAcore sensorgram depicted in Figure 18, reveals an increased response upon association of the complementary oligonucleotide sequence to the immobilized oligonucleotide, thus confirming the above immobilization technique.


54

Scheme 22

**Example 19. Synthesis of Anthracene-Silane Reagent (42)**

Scheme 23 illustrates the synthesis of an anthracene silane reagent for the functionalization of glass surfaces. Briefly, with reference to Scheme 23 hydroxymethylantracene (35) was reacted with CDI to form imidazolate (41). Imidazolate (41) was then reacted with propylamino silane (17), to provide anthracene-silane reagent (42), which was then used for glass derivatization as illustrated in Scheme 24 below.

Scheme 23



**Synthesis of anthracene-silane reagent (42).** To a stirring solution of (35) (4.8 mmol, 1.0 g) in DMF (16 mL, 0.3 M) was added CDI (5.28 mmol, 0.856 g). After 3 hours, the reaction was pushed to completion by the addition of CDI (1.06 mmol, 0.171 g). The complete formation of the imidazolate (41) was confirmed by  $^1\text{H}$  NMR, which showed that the methylene of the alcohol had shifted from 5.65 ppm to 6.45 ppm. This is characteristic of the expected shift. To this stirring solution was added

5 aminopropyltriethoxy silane (17) (4.8 mmol, 1.06 g). The reaction was placed under an argon atmosphere and allowed to stir overnight. The reaction was complete by  $^1\text{H}$  NMR, which showed that the methylene of the imidazolate had shifted from 6.45 ppm to 6.15 ppm, characteristic of conversion to the expected carbamate product (42).


To the NMR sample in  $\text{CDCl}_3$  was added  $\text{D}_2\text{O}$  (200  $\mu\text{L}$ ). The tube was vortexed  
 10 for 1 minute, and then a second  $^1\text{H}$  NMR analysis was performed and revealed that compound (42) was still intact. As a result, the reaction solution was concentrated under reduced pressure at  $40^\circ\text{C}$  to a dark orange oil. The oil was dissolved in  $\text{CH}_2\text{Cl}_2$  (250 mL) and washed with  $\text{H}_2\text{O}$  (150 mL). The organic phase was concentrated under reduced pressure at  $40^\circ\text{C}$  to obtain a dark orange oil. Upon standing, the oil turned into a  
 15 crystalline orange solid.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.46 (s, 1H), 8.37 (d, 2H,  $J = 9$  Hz), 7.99 (d, 2H,  $J = 8.4$  Hz), 7.50 (m, 4H), 6.11 (s, 2H), 4.95 (br t, 1H), 3.75 (dd, 6H,  $J = 10.5$  and  $14.1$  Hz), 3.2 (dd, 2H,  $J = 10.3$  and  $13.2$  Hz), 1.6 (m, 2H), 1.16 (t, 9H,  $J = 6.9$  Hz), 0.6 (t, 2H,  $J = 8.2$  Hz).  $^{13}\text{C}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  156.9, 131.6, 131.2, 129.2, 127.1, 126.8, 125.3, 124.4, 77.7, 77.3, 76.9, 59.2, 58.7, 43.8, 23.5, 18.5, 7.9. The crude  
 20 material was used, in the glass slide derivatization experiment illustrated in Example 20.

#### Example 20. Functionalization of Glass Slides with Anthracene-Silane Reagent (42)

Scheme 24 (Figure 19) illustrates the functionalization of glass microscope slides with anthracene-silane reagent (42).

25

Scheme 24



One half of a clean microslide (not pre-treated, VWR) was dipped into a suspension of reagent 42 (1.04 g) in toluene (50 mL) and  $\text{CH}_2\text{Cl}_2$  (10 mL) for 1 hour. The slide was then  
 30 removed from the suspension and blotted dry on a piece of filter paper. The slide was



- 5   sonicated sequentially in toluene, toluene/ethanol (1:1, v/v) and ethanol (100 mL, each).  
For drying the slide was placed in an oven at 80 °C overnight.

5 Table 1. Known Methods for Immobilizing Biomolecules.

Immobilization Chemistry	Reference	Process Time (conditions)
Hydrophobic (salt or detergent facilitated)	Nikifov <i>et al.</i> U.S. Patent No. 5,610,287 (1997)	overnight (RT)
Ionic (polylysine-coated microporous membrane+cDNA)	<sup>1</sup> Shalon <i>et al.</i> (1996) Brown <i>et al.</i> (1998)	2 hours (h) (80°C)
Disulfide formation	<sup>2</sup> Anderson <i>et al.</i> (1998) Rogers <i>et al.</i> (1999)	2 h (>2 $\mu$ M; RT)
Epoxide opening with 3'-amino oligonucleotide	<sup>3</sup> Stimpson (acid cat; 1995) Beattie (elev temp; 1995) Lamtire (KOH; 1994)	>1 h (50 $\mu$ g/mL in PBS; RT)
Epoxide opening with 3'- or 5'-hydroxyl of oligonucleotide	<sup>4</sup> Shi <i>et al.</i> (base cat; 1999)	12+h (0.25-10 $\mu$ M; 65°C)
Radical chemistry with -SH slides + underivatized oligonucleotides	Shi <i>et al.</i> (1999) (ref 4)	overnight (0.25-10 $\mu$ M; RT)
Activated polypropylene or glass + amino oligodeoxyribonucleotides, PCR-products and PNA-oligomers; Surfaces activated as: a) isothiocyanate (phenyldiisothiocyanate) b) succinimidyl carbonate (DSC) c) succinimidyloxalate (DSO) d) dimethylsuberimidate	<sup>5</sup> Beier and Hoheisel (1999)	a)-d) overnight (0.1-1 $\mu$ M, 37°C)
Gold surface + thioate oligonucleotides	<sup>6</sup> Beebe <i>et al.</i> (1995)	10+ hours (3-10 $\mu$ g/mL; RT)
Carboxy oligonucleotides + amine slide	<sup>7</sup> Joos <i>et al.</i> (1997)	1 h (max 50% yield; pH=3.6; 0.05-50 pmol/15 $\mu$ L; RT)
p-Nitrophenyl ester oligonucleotides + polylysine coated 96 well plates	<sup>8</sup> Nikiforov and Rogers (1995)	overnight (150-200 pmol/40-50 $\mu$ L; RT)
Carboxy plates + amino oligonucleotides	Joos <i>et al.</i> (1997) (ref. 7)	overnight (10 pmol/well; RT)
Biotin cDNA+Streptavidin-coated 96 well plates	<sup>9</sup> Holmstrom <i>et al.</i> (1993)	30 minutes (RT)
Hydrazide gel (3D) + aldehyde oligonucleotide	<sup>10</sup> Yershov <i>et al.</i> (1996)	48 h (quantitative; 20°C)
Functionalized polyacrylamide gel matrices+ oligonucleotides: a) hydrazide gel/amino oligo b) reductive amination (via NaCNBH <sub>3</sub> , Me <sub>3</sub> NBH <sub>3</sub> or	<sup>11</sup> Timofeev <i>et al.</i> (1996)	a) overnight (87%) b) 1.5 h (60-74% amine gel/ald oligo 94-97% aldehyde gel/amine oligo) c) overnight (35%)

PyrBH <sub>3</sub> ) c) 1° MsO-gel/amino oligo/K <sub>2</sub> CO <sub>3</sub> d) glutaraaldehyde gel/amino oligonucleotides		d) overnight (71%+17% non-specific binding) Note: All linkages were somewhat unstable in 0.1 M TEAA buffer (pH=7), 60°C; due to polymer degradation.
Maleimide surface/thiol oligonucleotides	<sup>12</sup> Chrissey <i>et al.</i> (1996)	5 min-8 h (0.1-0.5 μM; RT; 34-73%)
Isothiocyanate/amino oligonucleotides	<sup>13</sup> Guo <i>et al.</i> (1994)	1 h (0.1-20 mM; 37°C)
Amine 96 well plates/NHS ester oligonucleotides	<sup>14</sup> Running and Urdea (1990)	30 min (1.2 mM; RT)
Functionalized acrylamide derivatives/oligonucleotides a) bromoacetyl Biogel beads/thio oligonucleotides b) sulfhydryl beads (Biogel or trisacryl)/bromoacetyl oligonucleotides	<sup>15</sup> Fahy <i>et al.</i> (1993)	a) overnight (25 pmol/150 μL; pH 9; 5-43% yield)  b) overnight (500 pmol/ mL, pH=9)
Activated carboxylate filter membrane (act. w/ EDC)/ amino oligonucleotides	<sup>16</sup> Zhang <i>et al.</i> (1991)	15 min-2 h (RT; pH=8.4; 80- 90% attached w/ 90% specificity)
Boronic acid-modified protein/ hydroxamate modified protein (solution phase conjugation)	<sup>17</sup> Rogers <i>et al.</i> (1997)	30 min (RT)
Streptavidin agarose gel coated chip/ biotinylated cDNA	<sup>18</sup> Gilles <i>et al.</i> (1999)	120 s (electronic addressing)
Polystyrene or polycarbonate plates/anthraquinone oligos or cDNA with irradiation	<sup>19</sup> Koch <i>et al.</i> (1999)	10 min (0.3-20 μM)
Photochemical immobilization of anthraquinone-conjugated oligonucleotides, DNA, and PCR amplicons on a variety of solid surfaces	<sup>20</sup> Koch <i>et al.</i> (2000)	15 min (irradiation)

- 5 <sup>1</sup>Shalon *et al.* (1996) Genome Research 639-645; Brown and Shalon (1998) U.S. Patent No. 5,807,522.
- <sup>2</sup>Anderson and Rogers (1998) U.S. Patent No. 5,837,860; Rogers *et al.* (1999) Analytical Biochemistry 266:23-30.
- <sup>3</sup>Stimpson *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:6379-6383; Beattie *et al.* (1995)
- 10 Clin. Chem. 41:700-706; Lamture *et al.* (1994) Nucleic Acids Research 22:2121-25.
- <sup>4</sup>Shi and Boyce-Jacino (1999) U.S. Patent No. 5,919,626.
- <sup>5</sup>Beier and Hoheisel (1999) Nucleic Acids Research 27(9):1970-1977.
- <sup>6</sup>Beebe and Rabke-Clemmer (1995) U.S. Patent No. 5,472,881.
- <sup>7</sup>Joos *et al.* (1997) Analytical Biochemistry 247:96-101.
- 15 <sup>8</sup>Nikiforov and Rogers (1995) Analytical Biochemistry 227:201-209.
- <sup>9</sup>Holmstrom *et al.* (1993) Analytical Biochemistry 209:278-283.

- 5   <sup>10</sup>Yershov *et al.* (1996) Proc. Natl. Acad. Sci. USA 93:4913-4918.  
     <sup>11</sup>Timofeev *et al.* (1996) Nucleic Acids Research 24(16):3142-3148.  
     <sup>12</sup>Chrisey *et al.* (1996) Nucleic Acids Research 24(16):3031-3039.  
     <sup>13</sup>Guo *et al.* (1994) Nucleic Acids Research 22 (24):5456-5465.  
     <sup>14</sup>Running and Urdea (1990) BioTechniques 8 (3):276-277.  
10   <sup>15</sup>Fahy *et al.* (1993) Nucleic Acids Research 21(8):1819-1826.  
     <sup>16</sup>Zhang *et al.* (1991) Nucleic Acids Research 19(14):3929-3933.  
     <sup>17</sup>Rogers *et al.* (1997) Gene Therapy 4:1387-1392.  
     <sup>18</sup>Gilles *et al.* (1999) Nature Biotechnolgy 17:365.  
     <sup>19</sup>Koch *et al.* (Exiqon) 1999.  
15   <sup>20</sup>Koch *et al.* (2000) Bioconjugate Chem. 11:474-483.

5

**Table 2. Results from the Conjugation of Oligonucleotide (24) to maleimide CPG (Example 10)**

Concentration of (24) [nmol/ $\mu$ L]	ABS [ ]	CPG-Loading [ $\mu$ mol/g]
0.30	0.549	0.771
0.37	0.583	0.819
0.44	0.655	0.920
0.52	0.718	1.008
0.67	0.847	1.190
0.74	0.896	1.258
0.93	1.013	1.423
1.10	1.199	1.684

10

**Table 3. Time Dependence of the Reaction Between Oligonucleotide (24) and Maleimide CPG (Example 10)**

Reaction Time [min]	ABS [ ]	CPG-Loading [ $\mu$ mol/g]
5	0.300	0.421
10	0.363	0.510
20	0.440	0.618
40	0.548	0.770
60	0.628	0.882
90	0.658	0.924

5

**Table 4. Chromatography Conditions (Example 12)**

Time (min)	%Eluent B	Gradient method
0	0	Linear
10	10	Linear
27	15	Linear

**Buffer A:** 25 mM  $\text{Na}_2\text{HPO}_3$  solution (pH=7.5) with 10% EtOH.

**Buffer B:** 2M NaBr solution with 10% EtOH.

10

**Table 5. Chromatography Conditions (Example 13)**

Time (min)	%Eluent B	Gradient Method
0	0	Linear
21	30	Linear
22	100	Linear
32	100	Isocratic
33	0	Linear
42	0	Isocratic

**Eluent A:** TEAA (pH=7.0)

**Eluent B:** Acetonitrile

## 5 CLAIMS

1. A method for immobilizing a molecule on a support comprising the step of reacting a derivatized molecule with a derivatized support capable of reacting with said derivatized molecule via a cycloaddition reaction.

10 2. The method of claim 1 wherein said cycloaddition reaction is selected from the group consisting of a [1+2]-cycloaddition, [2+2]-cycloaddition, [3+2]-cycloaddition, [2+4]-cycloaddition, [4+6]-cycloaddition, and cheletropic reactions.

3. The method of claim 2 wherein said cycloaddition reaction is selected from  
15 the group consisting of a 1,3-dipolar cycloaddition, a Diels-Alder reaction, an ene reaction and a [2+2] photochemical cycloaddition reaction.

4. The method of claim 1 wherein said molecule is selected from the group consisting of a biomolecule, a macromolecule, and a diagnostic detector molecule (DDM).  
20

5. The method of claim 4 wherein said biomolecule is selected from the group consisting of nucleic acids, oligonucleotides, proteins, peptides and amino acids, polysaccharides and saccharides, glycoproteins and glycopeptides, alkaloids, lipids, hormones, drugs, prodrugs, antibodies and metabolites.  
25


6. The method of claim 4 wherein said DDM is selected from the group consisting of fluorescent, chemiluminescent, radioisotope and bioluminescent marker compounds; antibodies, biotin and metal chelates.

30 7. The method of claim 6 wherein said DDM is fluorescein.

8. The method of claim 1 wherein said molecule is derivatized with a moiety selected from the group consisting of a diene or dienophile, with or without heteroatoms, a 1,3-dipole or 1,3-dipolarophile, with or without heteroatoms, an ene or enophile, with or  
35 without heteroatoms a C2-C50 alkene, with or without heteroatoms, a C2-C50 alkyne, with or without a heteroatoms, aromatic compounds, carbenes and carbene precursors.

5


9. The method of claim 8 wherein said diene is selected from the group consisting of:



wherein

10

Z is a linker selected from the group consisting of:



wherein

$m, n, o$  are equal to 0, 1, 2 and

15


Y is selected from NH, O, NH(CO)O, NH(CS)O, NH(CO)NH, NH(CO), S-S-S-, Si(OR)<sub>3</sub> and SiR<sub>2</sub> wherein

R is selected from alkyl, aryl, substituted alkyl or substituted aryl.




5

10. The method of claim 8 wherein said dienophile is selected from the group consisting of:



wherein

10 Z is a linker selected from the group consisting of:



wherein

m, n, o are equal to 0, 1, 2 and


Y is selected from NH, O, NH(CO)O, NH(CS)O, NH(CO)NH, NH(CO), S-S-S-,

15 Si(OR)<sub>3</sub> and SiR<sub>2</sub> wherein

R is selected from alkyl, aryl, substituted alkyl or substituted aryl.

11. The method of claim 1 wherein said derivatized molecule is an oligonucleotide selected from the group of compounds having the following formulas:

65



5

wherein

B is a nucleobase;

A and A' are 2'-sugar substituents;

W is independently selected from the group consisting of an oligonucleotide  
10 having between 1-1000 nucleobases, X or H; and

X is a diene, dienophile, 1,3-dipole, 1,3 dipolarophile, ene, enophile, alkene,  
alkyne or other moiety, capable of undergoing a cycloaddition reaction, additionally when  
X is attached to nucleobase B it can be attached to a carbon atom, an exocyclic nitrogen or  
an exocyclic oxygen.

15

12. The method of claim 11 wherein

A and A' are independently selected from the group consisting of H,  $^2\text{H}$ ,  $^3\text{H}$ , Cl, F,  
OH,  $\text{NHOR}^1$ ,  $\text{NHOR}^3$ ,  $\text{NHNHR}^3$ ,  $\text{NHR}^3$ ,  $=\text{NH}$ ,  $\text{CHCN}$ ,  $\text{CHCl}_2$ , SH,  $\text{SR}_3$ ,  $\text{CFH}_2$ ,  $\text{CF}_2\text{H}$ ,  
 $\text{CR}_2\text{Br}$ ,  $-(\text{OCH}_2\text{CH}_2)_n\text{OCH}_3$ ,  $\text{OR}^4$ , and imidazole;

20  $\text{R}^1$  is selected from the group consisting of H and an alcohol protecting group;

$\text{R}^2$  is selected from the group consisting of  $=\text{O}$ ,  $=\text{S}$ , H, OH,  $\text{CCl}_3$ ,  $\text{CF}_3$ , halide,  
optionally substituted  $\text{C}_1$ - $\text{C}_{20}$  alkyl (including cyclic, straight chain, and branched),  $\text{C}_2$ - $\text{C}_{20}$   
alkenyl,  $\text{C}_6$ - $\text{C}_{20}$  aryl,  $\text{C}_1$ - $\text{C}_{20}$  acyl,  $\text{C}_1$ - $\text{C}_{20}$  benzoyl,  $\text{OR}_4$  and esters;

$\text{R}^3$  is selected from the group consisting of  $\text{R}^2$ ,  $\text{R}^4$ , CN,  $\text{C}(\text{O})\text{NH}_2$ ,  $\text{C}(\text{S})\text{NH}_2$ ,  
25  $\text{C}(\text{O})\text{CF}_3$ ,  $\text{SO}_2\text{R}^4$ , amino acid, peptide and mixtures thereof;

5           R<sup>4</sup> is selected from the group consisting of an optionally substituted hydrocarbon (C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>20</sub> alkenyl, C<sub>2</sub>-C<sub>20</sub> alkynyl), an optionally substituted heterocycle, t-butyltrimethylsilyl ether, triisopropylsilyl ether, nucleoside, carbohydrate, fluorescent label and phosphate; and

          X is selected from the group consisting of alkyl or substituted alkyl group bearing  
10 a conjugated diene unit, an alkoxy or substituted alkoxy group bearing a conjugated diene unit, CH<sub>2</sub>CHCH=CHCH<sub>2</sub>CH<sub>2</sub>O, maleimide substituted alkoxy groups, dienophile substituted alkoxy groups, an alkylamino group or substituted alkylamino group bearing a conjugated diene unit, maleimide substituted alkylamino groups or substituted alkylamino groups, an alkylamino group or substituted alkylamino group bearing a dienophile moiety,  
15 a nitrile ylid, nitrile imine, nitrile oxide, diazoalkane, azide, azomethine ylid, azomethine imine, nitron, carbonyl ylid, carbonyl imine and carbonyl oxide.

          13. The method of claim 1 wherein said support is selected from the group consisting of glass, polymers and resins, and large biomolecules.

20

          14. The method of claim 13 wherein said glass is selected from the group consisting of controlled pore glass (CPG), glass slides, glass fibers, glass disks and materials coated with glass.

25           15. The method of claim 13 wherein said polymers and resins are selected from the group consisting of polystyrene (PS), polyethylene glycol (PEG), copolymers of PS and PEG, copolymers of polyacrylamide and PEG and copolymers containing maleimide or maleic anhydride, polyvinyl alcohol and immunogenic high molecular weight compounds.

30

          16. The method of claim 13 wherein said large biomolecules are selected from the group consisting of polysaccharides, proteins and nucleic acids.


          17. The method of claim 1 wherein said support is a solid support.

35

- 5           18.    The method of claim 1 wherein said support is derivatized with a moiety selected from the group consisting of a diene or dienophile, with or without heteroatoms, a 1,3-dipole or 1,3-dipolarophile, with or without heteroatoms, an ene or enophile, with or without heteroatoms, a C2-C50 alkene, with or without heteroatoms, a C2-C50 alkyne, with or without heteroatoms, aromatic compounds, carbenes and carbene precursors.

10


19.    The method of claim 18 wherein said diene is selected from the group consisting of:



wherein

15

Z is a linker selected from the group consisting of:




wherein

5.  $m, n, o$  are equal to 0, 1, 2 and

Y is selected from NH, O, NH(CO)O, NH(CS)O, NH(CO)NH, NH(CO), S-S-S-, Si(OR)<sub>3</sub> and SiR<sub>2</sub> wherein


R is selected from alkyl, aryl, substituted alkyl or substituted aryl.

10            20.    The method of claim 19 wherein said dienophile is selected from the group  
consisting of:



wherein

Z is a linker selected from the group consisting of:



15

wherein

$m, n, o$  are equal to 0, 1, 2 and


Y is selected from NH, O, NH(CO)O, NH(CS)O, NH(CO)NH, NH(CO), S-S-S-,  
20 Si(OR)<sub>3</sub> and SiR<sub>2</sub> wherein

R is selected from alkyl, aryl, substituted alkyl or substituted aryl.

5

21. An immobilized product formed by the method of claim 1.

22. A compound selected from the group consisting of:



1/12



Fig. 1



Fig. 2

BEST AVAILABLE COPY

2/12



Fig. 3A

Fig. 3B




Fig. 4

BEST AVAILABLE COPY



3/12



Fig. 5A

Fig. 5B




Fig. 6

BEST AVAILABLE COPY

4/12

Placement of Solutions:Control:

Diene-Oligonucleo-  
tide 23, pure +  
Non-Functionaliz-  
ed Portion of Slide

Control:

Oligonucleotide 22 +  
Maleimide-Functiona-  
lized Portion of Slide

DA SurfaceImmobilization:

Diene-Oligonucleoti-  
de 23, pure +  
Maleimide-Function-  
alized Portion of  
Slide




Fig. 7




Fig. 8

BEST AVAILABLE COPY

5/12




Fig. 9




Fig. 10




Fig. 11





Fig. 12A

Fig. 12B

BEST AVAILABLE COPY


7/12



Fc	APROG	TIME	AbsResp	SLOPE	BASLINE	RelResp	ID
1	IMMOBILIZATION	252.5	13654.6	0.08	YES	0	BASLINE
2	IMMOBILIZATION	252.6	13709.9	0.04	YES	0	BASLINE
3	IMMOBILIZATION	252.7	13751.5	-0.04	YES	0	BASLINE
4	IMMOBILIZATION	252.8	13736.4	0.12	YES	0	BASLINE
1	IMMOBILIZATION	642.5	13721.9	0.00	YES	67.3	NHS
2	IMMOBILIZATION	642.6	13770.9	0.07	YES	61.0	NHS
3	IMMOBILIZATION	642.7	13813.7	-0.04	YES	62.2	NHS
4	IMMOBILIZATION	642.8	13799.1	-0.08	YES	62.7	NHS
1	IMMOBILIZATION	1430.5	13786.3	-0.03	YES	64.4	ETHYLENEDIAMINE
2	IMMOBILIZATION	1430.6	13847.8	0.01	YES	76.9	ETHYLENEDIAMINE
3	IMMOBILIZATION	1430.7	13894.7	-0.01	YES	81.0	ETHYLENEDIAMINE
4	IMMOBILIZATION	1430.8	13882.8	-0.01	YES	83.7	ETHYLENEDIAMINE
1	IMMOBILIZATION	2001.5	13782.4	0.05	YES	-4.0	ETHYLENEDIAMINE
2	IMMOBILIZATION	2001.6	13842.8	0.03	YES	-5.1	ETHYLENEDIAMINE
3	IMMOBILIZATION	2001.7	13888.6	-0.02	YES	-6.1	ETHYLENEDIAMINE
4	IMMOBILIZATION	2001.8	13876.1	0.01	YES	-6.7	ETHYLENEDIAMINE
1	IMMOBILIZATION	2681.5	13940.8	1.63	NO	158.4	MALEIMIDE_LEVEL
2	IMMOBILIZATION	2681.6	13994.6	0.90	NO	151.8	MALEIMIDE_LEVEL
3	IMMOBILIZATION	2681.7	14042.9	0.25	NO	154.2	MALEIMIDE_LEVEL
4	IMMOBILIZATION	2681.8	14040.0	-0.33	NO	164.0	MALEIMIDE_LEVEL

Figure 13


8/12



Fc	TIME	AbsResp	SLOPE	BASLINE	RelResp	ID
1	279.5	13922.6	-0.18	YES	0	MALEIMIDE BASE
1	3416.5	14660.0	-0.06	NO	737.4	5000-PEG-SH pH 6.5 ADDED

Figure 14


9/12



Fc	TIME	AbsResp	SLOPE	BASELINE	RelResp	ID
4	100.5	14414.7	-0.01	YES	0	MALEIMIDE BASELINE
4	448.5	14413.4	-0.01	NO	-1.3	500 nM 22-O7O-DIENE pH 6.5
4	1388.5	14409.8	-0.01	NO	-4.9	5500 nM 22O7O 10 uL/min
4	2600.5	14407.3	-0.01	NO	-7.4	5 uM 22-O7O-DIENE pH 6.5
4	26984.5	15697.7	-0.03	NO	1283.0	7.5 mM 5K-DIENE pH 6.5 DA1 ADDED
4	50200.5	16181.7	0.22	NO	1767.0	7.5 mM 5K-DIENE pH 6.5 DA2 ADDED
4	80000.5	16395.9	-0.01	NO	1981.2	7.5 mM 5K-DIENE pH 6.5 DA3 ADDED

Figure 15

10/12





Fc	TIME	AbsResp	SLOPE	BASELINE	RelResp	ID
4	120.5	14211.3	0.06	YES	0	MALEIMIDE BASELINE
4	3960.5	14343.4	-0.18	NO	132.1	5K-PEG-ANTH 1 HR
4	7960.5	14447.3	-0.04	NO	235.9	5K-PEG-ANTH 2 HR
4	11876.5	14551.6	-0.34	NO	340.3	5K-PEG-ANTH 3 HR
4	15826.5	14657.0	0.77	NO	445.6	5K-PEG-ANTH 4 HR
4	19810.5	14765.0	-0.09	NO	553.7	5K-PEG-ANTH 5 HR
4	23856.5	14894.7	0.00	NO	683.4	5K-PEG-ANTH 6 HR
4	27806.5	14992.8	-0.02	NO	781.5	5K-PEG-ANTH 7 HR
4	31730.5	15098.7	-0.05	NO	887.4	5K-PEG-ANTH 8 HR
4	35690.5	15198.9	-0.01	NO	987.5	5K-PEG-ANTH 9 HR
4	39614.5	15301.6	-0.22	NO	1090.3	5K-PEG-ANTH 10 HR
4	43612.5	15402.8	-0.16	NO	1191.5	5K-PEG-ANTH 11 HR
4	47572.5	15492.6	0.03	NO	1281.3	5K-PEG-ANTH 12 HR
4	51572.5	15550.1	0.04	NO	1338.7	5K-PEG-ANTH 13 HR
4	55500.5	15599.5	0.04	NO	1388.2	5K-PEG-ANTH 14 HR
4	60070.5	15647.1	-0.01	NO	1435.8	5K-PEG-ANTH 15 HR

Figure 16



11/12

*Figure 17**Figure 18*

12/12




Fig. 19

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/13956

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : G03C 5/00; C07H 19/00, 19/04

US CL : 430/8; 536/22.1, 26.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 430/296;

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**REFERENCES IN THE FILE**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, PUBMED-MED, STN, BIOSIS, EMBASE, CAPLUS, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,580,697(KEANA ET AL.) 03 December 1996, See entire document specially column 2, lines 22-67; column 3, lines 4-24; column 4, lines 47-50 and column 6, lines 55-58.	1-21
Y	WO 98/30575 (NEXSTAR PHARMACEUTICALS, INC.) 16 JULY 1998, See entire document specially claims 1-21.	1-21
A	KOCH et al., Polystyrene or polycarbonate plates/anthraquinone oligos or cDNA with irradiation, Exiqon , 1999, see whole documents.	1-21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 JULY 2001

Date of mailing of the international search report

24 AUG 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FARIBA GHASHGHAEI

Telephone No. (703) 3050196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/13956

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KOCH et al., Photochemical Immobilization of anthraquinone conjugated oligonucleotides and PCR amplicons on solid surfaces, Bioconjugate Chem., Vol. 11, 2000, pages 474-483, see entire document.	1-21

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/13956

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-21, drawn to a method for immobilizing a molecule on a support

Group II, claim 22, drawn to a compound selected from the group consisting of eleven different formulas with different structural features.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of group I relate to a method for immobilizing a molecule on a support comprising the step of reacting a derivatized molecule with a derivatized support capable of reacting with said derivatized molecule via a cycloaddition reaction, wherein the said molecule is derivatized with a moiety selected from the group consisting of a diene or dienophile with or without heteroatoms, an ene or enophile, with or without heteroatoms. However, the inventions of group II is related to a series of different formulas which is not related to the inventions of group I and has different technical features, because these compounds could be made with different methods such as any simple chemical synthesis.

BEST AVAILABLE COPY